



Universiteit
Leiden
The Netherlands

The two enantiomers of 2-hydroxyglutarate differentially regulate cytotoxic T cell function

Foskolou, I.P.; Cunha, P.P.; Sanchez-Lopez, E.; Minogue, E.A.; Nicolet, B.P.; Guislain, A.; ... ; Johnson, R.S.

Citation

Foskolou, I. P., Cunha, P. P., Sanchez-Lopez, E., Minogue, E. A., Nicolet, B. P., Guislain, A., ... Johnson, R. S. (2023). The two enantiomers of 2-hydroxyglutarate differentially regulate cytotoxic T cell function. *Cell Reports*, 42(9). doi:10.1016/j.celrep.2023.113013

Version: Publisher's Version
License: [Creative Commons CC BY 4.0 license](#)
Downloaded from: <https://hdl.handle.net/1887/3763584>

Note: To cite this publication please use the final published version (if applicable).

Article

The two enantiomers of 2-hydroxyglutarate differentially regulate cytotoxic T cell function

Iosifina P. Foskolou,^{1,2,3,4,*} Pedro P. Cunha,^{1,2} Elena Sánchez-López,⁵ Eleanor A. Minogue,¹ Benoît P. Nicolet,^{3,4} Aurélie Guislain,^{3,4} Christian Jorgensen,⁶ Sarantos Kostidis,⁵ Nordin D. Zandhuis,^{3,4} Laura Barbieri,¹ David Bargiela,¹ Demitris Nathanael,¹ Petros A. Tyrakis,¹ Asis Palazon,^{1,7,8} Martin Giera,⁵ Monika C. Wolkers,^{3,4} and Randall S. Johnson^{1,2,9,*}

¹Department of Physiology, Development and Neuroscience, University of Cambridge, Downing Site, Cambridge CB2 3EG, UK

²Department of Cell and Molecular Biology (CMB), Karolinska Institutet, Solnavägen 9, 171 65 Solna, Sweden

³Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory Amsterdam University Medical Center, University of Amsterdam, 1066 CX Amsterdam, the Netherlands

⁴Oncode Institute, 3521 AL Utrecht, the Netherlands

⁵Leiden University Medical Center, Center for Proteomics and Metabolomics, Albinusdreef 2, 2333ZA Leiden, the Netherlands

⁶Department of Chemistry, Aarhus University, Langelandsgade 140, 8000 Aarhus C, Denmark

⁷Present address: Cancer Immunology and Immunotherapy Lab, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, 48160 Derio, Spain

⁸Present address: Ikerbasque, Basque Foundation for Science, 48009 Bilbao, Bizkaia, Spain

⁹Lead contact

*Correspondence: i.foskolou@sanquin.nl (I.P.F.), rsj33@cam.ac.uk (R.S.J.)

<https://doi.org/10.1016/j.celrep.2023.113013>

SUMMARY

2-Hydroxyglutarate (2HG) is a byproduct of the tricarboxylic acid (TCA) cycle and is readily detected in the tissues of healthy individuals. 2HG is found in two enantiomeric forms: S-2HG and R-2HG. Here, we investigate the differential roles of these two enantiomers in cluster of differentiation (CD)8⁺ T cell biology, where we find they have highly divergent effects on proliferation, differentiation, and T cell function. We show here an analysis of structural determinants that likely underlie these differential effects on specific α -ketoglutarate (α KG)-dependent enzymes. Treatment of CD8⁺ T cells with exogenous S-2HG, but not R-2HG, increased CD8⁺ T cell fitness *in vivo* and enhanced anti-tumor activity. These data show that S-2HG and R-2HG should be considered as two distinct and important actors in the regulation of T cell function.

INTRODUCTION

There are four known metabolites with structural similarities to α -ketoglutarate (α KG) that inhibit a range of α KG-dependent enzymes. Two of these, succinate and fumarate, are tricarboxylic acid (TCA) cycle metabolites with essential metabolic roles; the third was recently revealed to be glutarate,¹ a product of amino acid catabolism. The fourth metabolite is 2-hydroxyglutarate (2HG), a physiological byproduct of the TCA cycle. 2HG has two enantiomers: the S-form (also known as L-2HG) and the R-form (also known as D-2HG). Intracellular accumulation of 2HG is derived by the reduction of α KG to either R-2HG or S-2HG.² Both enantiomers can be detected in most body fluids of healthy individuals, and their concentrations can reach near millimolar levels in urine and serum.^{3,4}

R-2HG is the most studied 2HG enantiomer due to its increased levels in tumors harboring mutations in isocitrate dehydrogenase (IDH1/2mut).^{2,5–7} R-2HG can also be physiologically formed by wild-type IDH enzymes and the promiscuous activity of 3-phosphoglycerate dehydrogenase (PHGDH).^{8,9} S-2HG accumulates in hypoxic and acidic conditions through the action of malate dehydrogenase 1 and 2 (MDH1 and MDH2) and lactate

dehydrogenase A (LDHA).^{9–11} S-2HG accumulation has also been reported in clear cell renal cell carcinomas (ccRCCs) and pancreatic cancers.^{12,13} However, the role of 2HG in tumorigenesis is more complex than initially thought. For example, patients with IDHmut glioma or acute myeloid leukemia (AML) tend to have better overall survival rates than patients with IDH wild-type (IDH-WT) gliomas or AML.^{6,7,14–16}

2HG accumulation is observed in both physiological and pathological conditions, and it is important to determine whether the two 2HG enantiomers act in a similar fashion in immune cells. As both enantiomers can affect cytotoxic T cell differentiation, proliferation, and function,^{2,11,17–19} we wished to determine their different roles in cluster of differentiation (CD)8⁺ T cell functions. We show that the two enantiomers differentially regulate T cell function.

RESULTS

Human CD8⁺ T cells express different surface markers when treated with cell-permeable S-2HG or R-2HG

The structural similarity of both 2HG enantiomers to α KG causes them to act as competitive inhibitors of α KG-dependent






Figure 1. Human CD8⁺ T cells express different surface markers when treated with OE-S-2HG or OE-R-2HG

(A) Schematic representation of the TCA cycle and chemical structures of α -ketoglutarate (α KG), S-2-hydroxyglutarate (S-2HG), and R-2-hydroxyglutarate (R-2HG).

(legend continued on next page)

enzymes (Figure 1A).^{20,21} To investigate the differential effects of the two enantiomers of 2HG on human T cells, we used cell-permeable octyl ester forms of S-2HG (OE-S-2HG) and R-2HG (OE-R-2HG). To minimize donor-to-donor variation, we isolated naive CD8⁺ T (T_N) cells from peripheral blood mononuclear cells (PBMCs) of healthy individuals, activated them with aCD3/aCD28, and treated them with the two OE-2HG enantiomers every 1–2 days. Neither OE-S-2HG nor OE-R-2HG had an effect on CD8⁺ T cell viability when used in physiologically relevant concentrations (0.4 mM)^{3,11} for up to 12 days of culture (Figure 1B).

Early after activation, CD8⁺ T cells treated with OE-S-2HG proliferated less (Figure S1A) and had a slower rate of cell division (day 4; Figure 1C) when compared with CD8⁺ T cells treated with OE-R-2HG or with vehicle. However, cell division of OE-S-2HG-treated CD8⁺ T cells remained stable over later time points when compared to day 4, whereas cell division of vehicle- and OE-R-2HG-treated CD8⁺ T cells was gradually and significantly decreased (Figure 1C). On day 12, OE-S-2HG-treated CD8⁺ T cells had a cell division rate of 1.169 ± 0.17 , followed by OE-R-2HG (1.049 ± 0.19) and vehicle (0.9879 ± 0.18) (Figure 1C). In sum, OE-S-2HG-treated CD8⁺ T cells proliferate slower after activation, but their proliferation is less decreased at later time points relative to OE-R-2HG- and vehicle-treated cells.

We then examined the effect of both enantiomers on the expression of several surface markers related to human CD8⁺ T cell differentiation. Increased concentrations of OE-S-2HG led to a dose-dependent increase of CD62L+/CD45RO+ (Figure 1D) and CCR7+/CD45RO+ (Figure S1B) CD8⁺ T cells, which are markers associated with early differentiated memory-like CD8⁺ T cells. Although increasing concentrations of OE-R-2HG increased the CCR7+/CD45RO+ population (Figure S1B), they led to a dose-dependent loss of CD62L and an increase in CD62L–/CD45RO+ cells (Figures 1D–1F). The differential expression of CD62L and CCR7 determines the differential migratory tendencies of CD8⁺ T cells. T cells expressing both CD62L and CCR7 can recirculate between lymphoid tissues and peripheral blood,²² whereas cells that express CCR7 but are CD62L– are usually T cells exiting peripheral tissues and are found in afferent lymphatics.^{23,24}

At 0.4 mM, both OE-S-2HG and OE-R-2HG significantly increased the CCR7+/CD45RO+ population compared with vehicle (Figure S1C), but only OE-S-2HG increased the CD62L+/CD45RO+ population compared with both vehicle and OE-R-2HG (Figure 1G). The OE-R-2HG enantiomer significantly increased the CD62L–/CD45RO+ and CD62L–/

CD45RO– populations, and decreased the CD62L+/CD45RO– populations, relative to treatment with either vehicle or OE-S-2HG (Figures 1H–1J). Neither OE-S-2HG nor OE-R-2HG had an effect on CCR7–/CD45RO+ and CCR7–/CD45RO– populations, and only OE-S-2HG-treated populations had decreased CCR7+/CD45RO– CD8⁺ T cells when compared with vehicle-treated cells (Figures S1D–S1F).

Interestingly, OE-R-2HG-treated CD8⁺ T cells increased expression of the homing marker CCR7 but decreased expression of the co-stimulatory marker CD28 relative to CD8⁺ T cells treated with OE-S-2HG (Figures S1G and S1H). OE-R-2HG-treated cells showed a moderate but not significant increase of the activation/checkpoint marker PD-1 and the transcription factor TOX (Figures S1I and S1J). In summary, CD8⁺ T cells treated with the two cell-permeable forms of 2HG show significant differences in cell division, proliferation, and expression of surface markers.

Transcriptome analysis reveals distinct differences between OE-S-2HG- and OE-R-2HG-treated human CD8⁺ T cells

To assess if the observed differences in cell proliferation and surface markers were due to transcriptome-related changes between OE-S-2HG- and OE-R-2HG-treated CD8⁺ T cells, we performed RNA sequencing (RNA-seq) analysis of CD8⁺ T_N cells early (day 5) and late (day 12) after activation. Cells were isolated, activated, and treated every 1–2 days with OE-S-2HG (0.4 mM), OE-R-2HG (0.4 mM), or vehicle (H₂O). Hierarchical clustering revealed distinct clusters of transcript expression depending on treatment with OE-S-2HG and OE-R-2HG, or vehicle, at both days 5 (Figure S2A) and 12 (Figure 2A). Volcano plot analysis identified a total of 361 differentially expressed genes (\log_2 fold change >0.5; adjusted p value [p.adj] < 0.05) between OE-S-2HG- and OE-R-2HG-treated cells on day 12 of treatment (Figure 2B). Hierarchical clustering of significant genes revealed differential expression of transcription factors in OE-S-2HG- and OE-R-2HG-treated cells (Figure 2C), as well as CD molecules and secreted molecules (Figures S2B and S2C). Interestingly, in concordance with protein measurements (Figures 1E, 1F, and S1H), OE-S-2HG-treated CD8⁺ T cells expressed higher *SELL* (CD62L) and *CD28* transcript levels compared with OE-R-2HG-treated cells (Figure 2B). Furthermore, OE-S-2HG-treated cells showed higher transcript levels of some genes that are preferentially expressed in CD8⁺ naive (T_N) and/or central memory (T_{CM}) T cells, including *SELL* (CD62L), *CD28*, *GPR15*, *NT5E* (CD73), *FUT7*, and *ZNF69* (Table S1; Figure 2B).

(B) Viability of CD8⁺ T cells as determined by automated cell counter. Data are represented as mean \pm SEM.

(C) Cell division of CD8⁺ T cells for the indicated days. Mixed-effects analysis with Tukey's multiple comparisons test was used (one test comparing treatment at different time points and one test comparing effect cell division at day 12 with day 4 for each treatment). Data are represented as mean \pm SEM.

(D) Flow cytometry plots of CD8⁺ T cells showing surface expression of CD62L and CD45RO. Representative plots of n = 3 are shown.


(E) Histograms of representative flow cytometry plots for CD62L expression on CD8⁺ T cells.

(F) Fold change of median fluorescence intensity (MFI) of CD62L for CD8⁺ T cells analyzed by flow cytometry. Each data point represents a donor (n = 9; 6 independent experiments). Unpaired two-tailed Student's t test was used.

(G–J) Frequency of (G) CD62L+/CD45RO+, (H) CD62L–/CD45RO+, (I) CD62L–/CD45RO–, and (J) CD62L+/CD45RO– cells is shown (%CD8⁺ T cells). Each data point represents a donor (n = 10; 7 independent experiments). Data are represented as mean \pm SEM. Repeated measures (RM) one-way ANOVA with Tukey's multiple comparisons test was used.

For all panels, naive CD8⁺ T cells were isolated, activated, and treated every 1–2 days with OE-S-2HG (0.4 mM), OE-R-2HG (0.4 mM), or vehicle (H₂O). Analysis was performed on day 12 unless otherwise stated. For all panels, *p \leq 0.05; **p \leq 0.01; ***p \leq 0.001; ****p \leq 0.0001.

See also Figure S1.



(legend on next page)

Using publicly available datasets, we observed that OE-R-2HG decreased the expression of genes whose expression is usually low in effector memory (T_{EM}) $CD8^+$ T cells when compared with T_{CM} cells, with the opposite being the case for OE-S-2HG-treated cells (Figure 2D). The gene signature of OE-R-2HG-treated cells was not typical of effector/effector memory cells, as markers associated with cytotoxicity and effector functions were lower in OE-R-2HG-treated cells relative to OE-S-2HG- and vehicle-treated cells (e.g., *ZFN683*, *HOPX*, *ZBTB32*, and *TBX21*) (Figures 2B and 2C). In addition, OE-R-2HG-treated cells expressed more *IKZF3* compared with OE-S-2HG-treated cells (Figures 2B and 2C); this gene was shown to be a repressor of effector function in $CD4^+$ T cells.²⁵

OE-S-2HG-treated cells increased expression of genes important for leukocyte cell adhesion (Figure 2E) and T cell activation (Figure S2D). Furthermore, gene set enrichment analysis (GSEA) revealed that OE-S-2HG-treated T cells displayed enrichment of genes associated with early T lymphocytes, cell-cycling genes, and E2F3 targets compared with OE-R-2HG (Figures S2E–S2G). E2F3 is a transcription factor that interacts directly with the retinoblastoma protein (pRB) to regulate the expression of genes involved in the cell cycle.²⁶ These results support our observation that OE-S-2HG-treated cells have a moderately higher cell division rate than OE-R-2HG-treated cells at day 12 of treatment (Figure 1C).

Finally, we questioned whether different time points of treatment with the two enantiomers (days 5 and 12) resulted in different gene expression profiles. Hierarchical clustering of the two time points showed close clustering of OE-R-2HG-treated $CD8^+$ T cells, indicating a treatment effect (Figure 2F). In addition, the two most separated T cell populations were those treated for 12 days with OE-R-2HG and OE-S-2HG (Figure 2F), indicating that the longer the cells are treated with either of the two 2HG compounds, the greater the divergence in their transcriptomes. This finding was supported by the \log_2 fold change (LFC) analysis of OE-R-2HG vs. OE-S-2HG at day 5 compared with day 12 (Figures 2G, S2H, and S2I). Interestingly, for OE-S-2HG-treated cells, genes such as *SELL*, *SELP*, *FUT7*, *GPR15*, *ZNF683*, *CCR1*, and *CCR4* were upregulated at both time points measured (Figure 2G). These data indicate that OE-S-2HG- and OE-R-2HG-treated cells have different transcriptional targets, which can explain some of the observed differences seen in $CD8^+$ T cell proliferation and differentiation after treatment with the two compounds.

S-2HG and R-2HG differentially inhibit specific α KG-dependent enzymes

We next studied the molecular mechanisms underlying the different transcriptional profiles of OE-S-2HG- and OE-R-2HG-treated $CD8^+$ T cells. Because of their structural similarities with α KG, both S-2HG and R-2HG can competitively inhibit α KG-dependent enzymes.^{20,21} Some α KG-dependent enzymes are epigenetic modulators, including histone and DNA demethylases.²¹ Therefore, we first assessed the effect of OE-S-2HG and OE-R-2HG treatments on histone modifications in $CD8^+$ T cells.

OE-S-2HG treatment significantly increased histone 3 lysine 9 acetylation (H3K9ac) compared with OE-R-2HG, whereas OE-R-2HG slightly increased H3K9 tri-methylation (H3K9me3) and significantly increased H3K9 di-methylation (H3K9me2) (Figures 3A and 3B). In addition, OE-R-2HG-treated cells increased H3K27me3 at the expense of H3K27ac compared with OE-S-2HG-treated cells (Figures 3A and 3C). These data are further supported by the broad increase of gene expression of histone deacetylase (HDAC) targets in OE-R-2HG-treated T cells and the decrease in the OE-S-2HG-treated samples (Figure S3A).

We next checked genes that are regulated by enhancer of zeste 2 (EZH2) and SUZ12, two members of the polycomb repressive complex 2 (PRC2), which regulates H3K27me deposition (Figure S3B).²⁷ EZH2 is essential for effector $CD8^+$ T cell expansion, and PRC2 deficiency impairs effector $CD8^+$ T cell differentiation but minimally impacts memory $CD8^+$ T cell maturation.²⁸ Target genes that are downregulated by SUZ12 were increased in OE-S-2HG-treated T cells and decreased in OE-R-2HG-treated T cells (Figure S3C). Similarly, EZH2-associated genes were significantly increased in OE-R-2HG-treated T cells (Figure S3D). To determine whether S-2HG or R-2HG could functionally alter the activity of histone demethylases, we performed *in vitro* enzymatic activity assays for the H3K9 demethylase KDM4C. In agreement with our cellular data, R-2HG was a more potent inhibitor than S-2HG, and the maximum percentages of KDM4C inhibition with our assay were 98% for R-2HG and 90% for S-2HG (Figure 3D).

We then checked the effect of OE-S-2HG and OE-R-2HG treatments on DNA methylation, which directly dictates $CD8^+$ T cell differentiation and function.²⁹ The ten-eleven translocation (TET) enzymes are α KG-dependent DNA demethylases that catalyze the oxidation of 5-methylcytosine (5mC) to

Figure 2. OE-S-2HG- and OE-R-2HG-treated human $CD8^+$ T cells have distinct transcriptomes

Naive $CD8^+$ T cells were isolated from 6 donors over 3 independent experiments, activated, and treated with OE-S-2HG (0.4 mM), OE-R-2HG (0.4 mM), or vehicle (H_2O). The cells were collected either on day 5 (3 donors) or on day 12 (3 donors), and RNA-seq analysis followed.

(A) Heatmap of hierarchically clustered genes at day 12 of culture.

(B) Volcano plot showing \log_2 fold change (LFC; x axis) and $-\log_{10}$ adjusted p value (y axis) of transcripts differentially expressed in OE-R-2HG-treated $CD8^+$ T cells vs. OE-S-2HG-treated $CD8^+$ T cells (day 12). Colored dots represent LFC >0.5 (blue) or <-0.5 (red) and adjusted p value [p.adj] <0.05.


(C) Heatmap of hierarchically clustered genes in $CD8^+$ T cells (day 12). Statistically significant differentially expressed hits of transcription factors are shown.

(D and E) Heatmaps of standardized gene expression (Z score) in treated $CD8^+$ T cells (day 12): (D) downregulated genes in T_{EM} cells compared with T_{CM} cells, and (E) genes involved in leukocyte cell adhesion. Gene sets were obtained from ToppGene. Red and blue colors indicate increased and decreased expression, respectively. Genes marked with “§” were non-statistically significant hits.

(F) Heatmap of hierarchically clustered genes in $CD8^+$ T cells at days 5 and 12 of culture.

(G) LFC of OE-R-2HG vs. OE-S-2HG on day 5 compared with on day 12. Dotted lines represent absolute LFC of 0.5. The red dots indicate statistically significant genes for OE-S-2HG upregulated at day 12 (LFC >0.5), which were also either upregulated or unchanged at day 5 (LFC > -0.5). The purple dots indicate statistically significant genes for OE-R-2HG upregulated at day 12 (LFC < -0.5), which were also either upregulated or unchanged at day 5 (LFC <0.5).

See also Figure S2 and Table S1.



(legend on next page)

5-hydroxymethylcytosine (5hmC).^{30,31} To determine if OE-S-2HG or OE-R-2HG treatment affects DNA methylation, we isolated CD8⁺ T_N cells, activated and treated them for 7 days with OE-S-2HG (0.4 mM), OE-R-2HG (0.4 mM), or vehicle (H₂O), and determined total 5hmC levels by flow cytometry (Figure S3E). Although both OE-S-2HG and OE-R-2HG lowered the 5hmC levels compared with vehicle, no differences were observed between OE-S-2HG and OE-R-2HG treatments in overall 5hmC levels (Figure S3F). We then performed *in vitro* enzymatic activity assays for TET2 using methylated single-stranded DNA (ssDNA) as a substrate. *In vitro*, R-2HG inhibited TET2 slightly more than S-2HG: the maximum inhibition values of TET2 with our assay were 77% for R-2HG and -57% for S-2HG (Figure 3E).

To gain a structural insight into the different inhibitory potencies of the 2HG metabolites, we investigated the conformation of KDM4C (PDB: 4XDO; resolution 1.97 Å) bound with αKG, S-2HG, or R-2HG (Figures 3F–3H and S3G–S3I). Both S-2HG and R-2HG can bind to the active site of the enzyme, albeit in a distorted bidentate coordination when compared with αKG, since the keto carboxyl end of αKG is replaced by a hydroxyl group in S-2HG and R-2HG (Figures 3I–3K). The bidentate coordination of the active site of αKG-dependent enzymes is sensitive to minimal changes,³² which explains why both S-2HG and R-2HG can act as inhibitors of KDM4C. R-2HG showed a nearly identical orientation to αKG in the catalytic core of KDM4C, in close proximity to Fe(II) (Figures 3H, 3K, and S3I). In contrast, S-2HG has to twist to find the right conformation in the catalytic core of KDM4C (Figures 3G, 3J, and S3G), which potentially explains why S-2HG is a less effective inhibitor of KDM4C. Collectively, these results highlight that S-2HG and R-2HG can have different affinities for different targets, which may result in different cellular effects.

OE-S-2HG and OE-R-2HG treatments affect T cell intracellular amino acid and lipid levels

To investigate the intracellular metabolic roles of S-2HG and R-2HG (Figure 4A), we performed nuclear magnetic resonance (NMR)-based metabolomics on CD8⁺ T cells treated with OE-S-2HG, OE-R-2HG, or vehicle. We isolated human total CD8⁺

and CD8⁺ T_N cells and then activated and treated them with OE-S-2HG (0.4 mM), OE-R-2HG (0.4 mM), or vehicle (H₂O) every 1–2 days for the indicated times (Figures 4 and S4).

For total CD8⁺ T cells, there were no differences between treatments in the levels of glucose and pyruvate either before or after activation (days 4 and 12) (Figures S4A and S4B). At day 4 after activation, lactate levels were significantly decreased in OE-S-2HG-treated compared with vehicle-treated CD8⁺ T cells; at day 12, lactate levels were lower than on day 4 and were similar between treatments (Figure S4C). Early after activation, CD8⁺ T cells utilize glycolysis to boost growth and maintain high proliferation rates. The fact that OE-S-2HG-treated cells had lower lactate levels compared with vehicle at day 4 after activation (Figure S4C) is in agreement with the lower cell division rates observed on the same day (Figures 1C and S1A). We also checked the intracellular levels of 2HG for both OE-S-2HG- and OE-R-2HG-treated CD8⁺ T cells. Surprisingly, we observed higher accumulation of free R-2HG than of S-2HG in the respectively treated CD8⁺ T cells, although the OE forms of 2HG were found intracellularly at similar levels for both OE-S-2HG- and OE-R-2HG-treated cells (Figures S4D and S4E). This result would imply that S-2HG might be more efficiently utilized and/or exported than R-2HG in human CD8⁺ T cells.


We then checked the levels of different metabolites in isolated CD8⁺ T_N cells activated and treated with OE-S-2HG (0.4 mM), OE-R-2HG (0.4 mM), or vehicle for 7 days. No differences were observed between treatments in the levels of glucose and lactate at day 7 after activation (Figure 4B). OE-S-2HG- and OE-R-2HG-treated CD8⁺ T cells had similar levels of the TCA metabolites citrate and succinate (Figure 4C). However, OE-S-2HG and OE-R-2HG treatments showed differences in the levels of metabolites closely related to the TCA cycle (Figure 4A). Both OE-S-2HG- and OE-R-2HG-treated cells had lower levels of aspartate and its downstream amino acid asparagine compared with the vehicle-treated cells (Figure 4D). OE-R-2HG-treated cells had lower levels of glutamate and its downstream metabolite glutathione (reduced form) compared with vehicle and OE-S-2HG (for glutamate) treatments (Figure 4E). Aspartate and glutamate are produced in part by enzymes that use αKG in the reactions

Figure 3. S-2HG and R-2HG have different inhibition potencies for some αKG-dependent enzymes

- (A) Western blot analysis of naive CD8⁺ T cells activated and treated every 1–2 days with OE-S-2HG (0.4 mM), OE-R-2HG (0.4 mM), or vehicle (H₂O) for 12 days. Representative images of n = 4 are shown.
- (B and C) Quantification of the expression levels of different histone marks shown in (A) relative to total H3 for (B) H3K9 and (C) H3K27. Each data point represents a donor (n = 4–5; 4 independent experiments). Data are represented as mean ± SEM. Unpaired two-tailed Student's t test was used.
- (D) *In vitro* enzymatic inhibition assay for the KDM4C enzyme. Inhibition was determined by using increasing concentrations of S-2HG or R-2HG. Data are represented as mean ± SD (n = 4; 2 independent experiments). Results are shown as non-linear fit (inhibitor vs. response four parameters variable slope), and two-way ANOVA was used. The statistical analysis shown is concentration × metabolite.
- (E) *In vitro* enzymatic inhibition assay for the TET2 enzyme. Inhibition was determined by using increasing concentrations of S-2HG or R-2HG. Data are represented as mean ± SD (n = 6; 3 independent experiments). The results are shown as non-linear fit (inhibitor vs. response four parameters variable slope), and two-way ANOVA was used. The statistical analysis shown is concentration × metabolite.
- (F–H) Representative snapshots of the catalytic site of KDM4C protein (PDB: 4XDO; resolution 1.97 Å) in complex with (F) αKG (KDM4C:2OG:Fe(II)), (G) S-2HG (KDM4C:2HG-(S):Fe(II)), and (H) R-2HG (KDM4C:2HG-(R):Fe(II)).
- (I) αKG (KDM4C:2OG:Fe(II)) maintains the pocket integrity from the crystal structure and is found in a bidentate coordination.
- (J) In KDM4C:2HG-(S):Fe(II), the backbone of S-2HG rearranges to maintain a pseudo-bidentate coordination of Fe(II).
- (K) In KDM4C:2HG-(R):Fe(II), the backbone of R-2HG resembles αKG, and no conformational rearrangement occurs. The enzymatic pockets of KDM4C:2HG-(S):Fe(II) and KDM4C:2HG-(R):Fe(II) contain additional waters near the coordination sphere of Fe(II) as a result of the disruption induced by the change from αKG to S-2HG or R-2HG.

For (A), uncropped and ladder images are deposited in Mendeley Data. For all panels, *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001.

See also Figure S3.



(legend on next page)

they catalyze (α KG-dependent transaminases) (Figure S4F). R-2HG can inhibit the α KG-dependent transaminases BCAT1/2 (branched chain amino acid transaminases 1/2) more potently than S-2HG, and R-2HG accumulation lowers glutamate production in glioblastoma cells.³³ This is in agreement with our observations in CD8⁺ T cells (Figure 4E) and implies that the reduction of glutamate in OE-R-2HG-treated cells could be in part due to the differential inhibition of α KG-dependent transaminases.

We also observed differences in the levels of other amino acids and phospholipids. Specifically, OE-S-2HG-treated cells had higher levels of glycine and proline compared with OE-R-2HG-treated cells (Figure 4F). OE-S-2HG-treated cells had also higher levels of the phospholipid precursors phosphoethanolamine (compared with vehicle-treated cells) and phosphocholine (compared with OE-R-2HG-treated cells), whereas OE-R-2HG-treated cells increased phosphatidylcholine (Figure 4G). Phosphoethanolamine is converted to phosphatidylethanolamine (PE), which together with phosphatidylcholine (PC) comprise most of the mitochondrial membrane lipids.³⁴ Interestingly, synthesis of another essential phospholipid for mitochondrial membranes maintains CD8⁺ T cell function, mitochondrial fitness, and memory differentiation.³⁵ In sum, OE-S-2HG- and OE-R-2HG-treated cells have distinct differences in central carbon metabolism, which could affect multiple aspects of CD8⁺ T cell function and differentiation.

OE-S-2HG-treated, but not OE-R-2HG-treated, mouse CD8⁺ T cells show increased tumor infiltration and anti-tumor activity

We next investigated the functional consequences of the observed differences between OE-S-2HG- and OE-R-2HG-treated CD8⁺ T cells in murine adoptive cell transfer (ACT) *in vivo* models. Prior to adoptive T cell transfer, we determined the expression of CD44 (adhesion receptor), CD62L, CD25 (interleukin-2 receptor A), CTLA4 (immune checkpoint receptor), ICOS (T cell co-stimulator), and granzyme B (GzmB) (effector molecule) of the mouse CD8⁺ T cells treated with vehicle, OE-S-2HG, or OE-R-2HG (Figures S5A and S5B). Even though mouse CD8⁺ T cells treated with OE-R-2HG do not lose CD62L expression as their human counterparts do (Figures S5B and 1E), we detected more CD62L+/CD44+ (T_{CM}) mouse CD8⁺ T cells when treated with OE-S-2HG compared with treatment with OE-R-2HG or vehicle (Figure S5A).

B16-OVA-bearing C57BL/6j mice treated with cyclophosphamide on day 11 received congenically marked OT-I CD8⁺ T cells at day 14 that were pre-treated with OE-S-2HG, OE-R-2HG, or vehicle (H₂O) (Figure 5A). Five days later, we analyzed the infiltrated OT-I T cells in the tumors, spleens, and lymph nodes.

The overall numbers of OT-I cells in the tumors were higher when T cells were pre-treated with OE-S-2HG compared with vehicle (Figures 5B and S5C). Also, even though similar numbers of OT-I cells were found in spleens (Figure S5D), mice that received OE-S-2HG-treated OT-I cells had significantly bigger spleens than the mice that received vehicle-treated OT-I cells (Figure S5E). Within the draining or non-draining lymph nodes, there were no differences in the numbers of OT-I T cells between treatments (Figure S5F).

Tumor-infiltrating OT-I T cells treated with OE-S-2HG expressed more CD44+/CD62L+ (T_{CM}) than OE-R-2HG- and vehicle-treated cells (Figure 5C). The activation marker PD-1 was unaltered in these cells (Figure 5D). We then checked the proliferation potential of the tumor-infiltrated OT-I cells by staining for Ki67. Although the percentage of OT-I cells positive for Ki67 was similar between treatments (Figure S5G), the number of Ki67+ cells was increased in tumors of mice that received OE-S-2HG-treated OT-I cells compared with vehicle-treated cells (Figure 5E). We also found more GzmB-expressing OT-I cells between OE-S-2HG and vehicle, similar to what was seen in our *in vitro* data (Figures 5F, S5A, and S5B).

Tumor-infiltrating lymphocytes (TILs) usually lose the capacity to react to T cell receptor (TCR) activation upon extraction from the tumor.³⁶ To investigate whether the treatment with the 2HG enantiomers could reverse this TCR block, we checked effector molecule production with or without *in vitro* restimulation with the cognate OVA₂₅₇₋₂₆₄ peptide. OE-S-2HG-treated OT-I cells significantly increased the percentage and the expression of the cytokine interferon γ (IFN γ) after OVA restimulation (Figures 5G and 5H), which implies that the tumor-infiltrated OT-I cells had decreased anergy. OE-S-2HG-treated OT-I cells also increased the percentage of positive cells, but not the expression levels, of the cytokine tumor necrosis factor α (TNF- α) after restimulation (Figures 5I and S5H). We also checked the degranulation marker CD107a and found increased expression levels, but not the percentage, after restimulation only in OE-S-2HG-treated OT-I cells (Figures 5J and S5I). In contrast, OE-R-2HG- and vehicle-treated OT-I cells did not show increased expression after OVA restimulation for any of the tested markers. The fact that a high percentage of OE-S-2HG-treated OT-I cells were preserved in a T_{CM} (CD44+/CD62L+) phenotype within the tumor might explain the decreased anergy we observed when restimulating these cells *in vitro*.

We then determined the effect of both 2HG enantiomers on CD8⁺ T cell anti-tumor activity by injecting C57BL/6j mice with B16-F10 OVA-expressing tumor cells and adoptively transferring OT-I CD8⁺ T cells that had been pre-treated with OE-S-2HG, OE-R-2HG, or vehicle (Figure 5K). At days 14 and 21 after ACT, we


Figure 4. Metabolic changes in OE-S-2HG- and OE-R-2HG-treated naive CD8⁺ T cells

(A) Schematic representation of basic intracellular metabolic pathways.

(B–G) Naive CD8⁺ T cells were isolated from 4 donors (one of the dots is 2 donors pooled; 2 donors for OE-R-2HG), activated, and treated every 1–2 days with OE-S-2HG (0.4 mM), OE-R-2HG (0.4 mM), or vehicle (H₂O). The cells were collected on day 7, and NMR-based metabolomics analysis followed. The levels of (B) glucose and lactate; (C) citrate and succinate; (D) aspartate and asparagine; (E) glutamate and glutathione (reduced form); (F) glycine and proline; and (G) O-phosphoethanolamine, O-phosphocholine, and phosphatidylcholine are shown.

For all panels, data are represented as mean \pm SEM, and ordinary one-way ANOVA with Tukey's multiple comparisons tests were used. For all panels, *p \leq 0.05; **p \leq 0.01; ***p \leq 0.001; ****p \leq 0.0001.

See also Figure S4.



(legend on next page)

determined the number of OT-I T cells in circulation by flow cytometry (Figure 5K). We found significantly more OE-S-2HG-treated OT-I cells in circulation compared with OE-R-2HG- (day 14) and vehicle-treated (days 14 and 21) OT-I T cells (Figure S5J). Also, the percentage of CD62L+/CD44+ cells was higher for OE-S-2HG-treated OT-I cells compared with vehicle at day 21 (Figure S5K). OE-S-2HG-treated OT-I cells had also increased CD127 (interleukin-7 receptor A) expression compared with vehicle at day 21 (Figure S5L).

Finally, we measured the effect of 2HG enantiomers on T cells relative to their capacity to control tumor growth. OE-S-2HG-treated OT-I cells had superior anti-tumor activity compared with all other conditions tested (OE-R-2HG, vehicle, and PBS, no T cell control), resulting in delayed tumor growth and increased survival (Figures 5L–5N). In contrast, OE-R-2HG OT-I cells had no beneficial effect on anti-tumor activity compared with vehicle-treated OT-I cells (Figure 5L–5N). This result can be explained by the increased number of TILs observed in the tumors (Figure 5B) and that these TILs express more GzmB and can produce high amounts of cytokines after *in vitro* restimulation (Figures 5F–5J). Thus, the differences in gene expression, differentiation status, and function observed in OE-S-2HG-treated CD8+ T cells result in improved anti-tumor activity.

DISCUSSION

Owing to the description of 2HG as an oncometabolite, there are currently many studies of 2HG in T cell immunology and some

with contradictory findings. Bunse et al. reported that non-cell-permeable tumor-derived R-2HG can be taken up by human CD8+ T cells through the sodium-dependent dicarboxylate transporter 3 (SLC13A3) and that R-2HG accumulation in CD8+ T cells suppresses proliferation and anti-tumor activity.³⁷ Notarangelo et al. showed that the effect of non-cell-permeable R-2HG on the impairment of CD8+ T cells is transient and relies on inhibiting the LDH enzyme.¹⁹ Conversely, Bottcher et al. failed to detect impaired CD4+ or CD8+ T cell proliferation or increased cell death when cells were cultured with R-2HG. Rather, they found that R-2HG increased the frequency of regulatory T cells (Tregs).³⁸ Other studies concluded that R-2HG accumulation in IDH mutant tumors inhibits both CD8+ T cell function and anti-tumor activity.^{39–42}

There are also contradictory data for S-2HG, although fewer studies have been conducted. Gupta et al. reported that pancreatic cancers accumulate S-2HG due to the promiscuous activity of LDHA and that LDHA inhibition increased CD8+ T cell infiltration. The authors used high concentrations of cell-permeable S-2HG *in vitro*, observed a reduction in CD8+ T cell migration, and concluded that S-2HG suppresses anti-tumor activity.¹³ In contrast, we reported that exogenous treatment of mouse and human CD8+ T cells with OE-S-2HG favors a memory phenotype and increases anti-tumor activity in multiple adoptive T cell transfer models.^{11,17}

Here, we show that treatment of human CD8+ T cells with esterified S-2HG or R-2HG differentially modulates CD8+ T cell proliferation and differentiation, which is reflected in their

Figure 5. OE-S-2HG-treated mouse CD8+ T cells show increased tumor infiltration and anti-tumor activity

- (A) Schematic representation of the adoptive cell therapy (ACT) *in vivo* model. B16-OVA-tumor-bearing C57BL/6j mice (CD45.1+/CD45.2+) were lymphodepleted with cyclophosphamide and adoptively transferred with CD45.2+ OT-I CD8+ T cells, which were previously activated and treated *in vitro* with OE-S-2HG (0.4 mM), OE-R-2HG (0.4 mM), or vehicle (H₂O) for 7 days.
- (B) Number of OT-I cells per mg of tumor (n = 9–11 mice per condition, two independent experiments; non-parametric Kruskal-Wallis with Dunn's multiple comparisons test).
- (C) Frequency of OT-I cells expressing CD62L+/CD44+ infiltrated in the tumors (n = 14–15 mice per condition, three independent experiments; ordinary one-way ANOVA with Holm-Sidak's multiple comparisons test).
- (D) Frequency of OT-I cells expressing PD-1 infiltrated in the tumors (n = 9–10 mice per condition, two independent experiments; ordinary one-way ANOVA with Tukey's multiple comparisons test).
- (E) Number of OT-I cells in the tumors positive for Ki67 per mg of tumor (n = 9–11 mice per condition, two independent experiments; non-parametric Kruskal-Wallis with Dunn's multiple comparisons test).
- (F) Frequency of OT-I cells infiltrated in the tumors expressing GzmB (n = 8–9 mice per condition, two independent experiments; non-parametric Kruskal-Wallis with Dunn's multiple comparisons test).
- (G–J) *In vitro* restimulation of OT-I tumor-infiltrated lymphocytes with OVA_{257–264} (100 nM) peptide.
- (G) Frequency of OT-I cells expressing IFN γ with (+OVA) or without (–OVA) restimulation.
- (H) IFN γ MFI of OT-I cells (CD45.2+, IFN γ +) cells with (+OVA) or without (–OVA) restimulation.
- (I) Frequency of OT-I cells expressing TNF- α with (+OVA) or without (–OVA) restimulation.
- (J) CD107a MFI of OT-I cells (CD45.2+, CD107a+) cells with (+OVA) or without (–OVA) restimulation.
- (K) Schematic representation of the ACT *in vivo* model. B16-F10-OVA-bearing C57BL/6j mice were lymphodepleted with cyclophosphamide and adoptively transferred with PBS or CD45.1+ OT-I CD8+ T cells, which were activated and treated *in vitro* with OE-S-2HG (0.4 mM), OE-R-2HG (0.4 mM), or vehicle (H₂O) for 7 days.
- (L) Tumor growth for each condition. Thin lines represent tumor growth from individual mice, and thick lines represent median tumor sizes for each group.
- (M) Combined data from (L).
- (N) Survival curves for tumor growth shown in (L) and (M). Threshold for survival was set at 500 mm³. Green line: PBS (n = 5 mice); gray line: vehicle (H₂O) (n = 6 mice); blue line: OE-R-2HG (n = 6 mice); red line: OE-S-2HG (n = 6 mice). Log-rank (Mantel-Cox) test was used. A similar tumor growth experiment with an EG7-OVA-expressing tumor model is deposited in Mendeley Data.
- For (B)–(F), median and min to max with all points (individual mice) are shown. For (G)–(J), violin plots with median and all points (individual mice) are shown. Representative of n = 2–3 independent experiments is shown (cumulative data from n = 3 are deposited in Mendeley Data). One-way ANOVA with Tukey's multiple comparisons was used between treatments, and paired two-tailed Student's t test was used for each treatment with (+OVA) compared with without (–OVA) restimulation. For (B) and (E), cell number was defined by counting beads. For all panels, *p \leq 0.05; **p \leq 0.01; ***p \leq 0.001; ****p \leq 0.0001. See also Figure S5.

differential gene expression of transcription factors, CD molecules, and secreted molecules. OE-S-2HG-treated CD8⁺ T cells expressed more memory-like markers and had a higher proliferative potential, a feature that is key for long-term effective T cell responses *in vivo*. Concurrently, OE-S-2HG-treated cells retained expression of effector molecule transcripts. This was reflected also in our *in vivo* experiments, where pre-treatment with OE-S-2HG increased the amount of functional tumor-infiltrated T cells and showed that these cells had increased cytotoxic potential when rechallenged *in vitro*.

We also note aspects of the molecular mechanisms of the divergent effects of the 2HG enantiomers. S-2HG and R-2HG had different inhibitory potencies for specific αKG-dependent enzymes, and R-2HG was a more potent inhibitor than S-2HG of the KDM4C enzyme. Chowdhury et al. showed that S-2HG inhibits more potently than R-2HG the FIH (factor inhibiting HIF), PHD2 (prolyl hydroxylase domain 2), and ALKBH2 (αKG-dependent dioxygenase homolog 2) enzymes, but, similarly to our results, they found that R-2HG inhibits KDMs with greater potency.²¹ R-2HG and S-2HG can also have different potencies for αKG-dependent transaminases,³³ which results in differential accumulation of specific metabolites and amino acids. We observed that OE-R-2HG-treated cells had lower glutamate and glutathione levels, whereas OE-S-2HG-treated cells had increased glycine and proline levels. Glutathione is an important non-enzymatic anti-oxidant that balances reactive oxygen species (ROS) intracellular levels, and failure to buffer accumulating ROS can block T cell activation.⁴³ Glycine is a building block for glutathione and a contributor to nucleotide synthesis, which maintains T cell proliferation.⁴⁴

OE-S-2HG and OE-R-2HG pre-treatments of adoptively transferred OT-I CD8⁺ T cells showed diverged T cell function in our tumor models. Specifically, OE-S-2HG-treated OT-I cells preferentially migrated to tumor sites and preserved their T_{CM} phenotype both within the tumor and in circulation. OE-S-2HG-treated OT-I cells also expressed more GzmB within tumors and produced ample amounts of effector molecules after *in vitro* restimulation. The above is an important characteristic of functional memory CD8⁺ T cells. The increased functionality of the OE-S-2HG-pre-treated OT-I cells was also demonstrated by their increased anti-tumor activity. Interestingly, although OE-R-2HG-pre-treated OT-I cells did not show a beneficial anti-tumor effect, they did not perform worse than the vehicle-treated cells in our *in vivo* models. This is in agreement with previously published data reporting that R-2HG's presence is required for CD8⁺ T cell impairment.¹⁹ However, the effect that OE-S-2HG has on CD8⁺ T cells is not transient and seems to be maintained weeks after treatment.

In conclusion, OE-S-2HG pre-treatment before ACT increases CD8⁺ T cell fitness and enhances anti-tumor activity. Clearly, S-2HG and R-2HG are not merely enantiomeric forms but have distinct functions in CD8⁺ T cell biology.

Limitations of the study

Some of the observed differences in our study could be attributed to the different intracellular accumulation and/or utilization of the free S-2HG and R-2HG despite the similar intracellular levels of their esterified forms (OE-S-2HG, OE-R-2HG). Also, in

the tumor growth/survival experiment, female mice were used. Additional experiments with male mice could increase our research generalizability.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
 - Lead contact
 - Materials availability
 - Data and code availability
- EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS
 - Mice
 - Human and mouse T cell cultures and treatments
- METHOD DETAILS
 - Flow cytometry
 - Western blots and 5hmC staining
 - RNA-Seq analysis and GSEA
 - *In vitro* enzymatic activity assays
 - Quantification of R- and S-2HG by LC-MS
 - NMR-based metabolomics
 - Simulations
 - Animal studies
- QUANTIFICATION AND STATISTICAL ANALYSIS
 - BioRender images

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.celrep.2023.113013>.

ACKNOWLEDGMENTS

We thank Darren Cawkill, Mark Hoogenboezem, Ken G.C. Smith, and Pedro Velica for helpful comments and advice and Cristina M. Branco for recruitment and support of P.P.C.; the Cambridge NIHR BRC Cell Phenotyping Hub and the flow cytometry facility from the School of the Biological Sciences; and the animal caretakers of the NKI and the Sanquin FACS facility. This work was supported by Apollo Therapeutics, the Knut and Alice Wallenberg Scholar Award, the Swedish Medical Research Council (Vetenskapsr det 2019-01485), the Swedish Cancer Fund (Cancerfonden, CAN2018/808), the Swedish Children's Cancer Fund (Barncancerfonden PR2020-007), and the Wellcome Trust Principal Fellowship Award (214283/Z/18/Z) to R.S.J.; the Evelyn Trust Cambridge (Patrick Sisson's Research Fellowship) and the Karolinska Institutet (Jonas S derquists Fellowship) awarded to I.P.F.; and the Foundation for Science and Technology of Portugal (FCT) scholarship (SFRH/BD/115612/2016) awarded to P.P.C.

AUTHOR CONTRIBUTIONS

Conceptualization, I.P.F. and R.S.J.; methodology, I.P.F., P.P.C., E.S.-L., C.J., and R.S.J.; software, B.P.N., D.B., and C.J.; investigation, I.P.F., P.P.C., E.S.-L., E.A.M., A.G., C.J., S.K., N.D.Z., L.B., and D.N.; writing – original draft, I.P.F. and R.S.J.; writing – review & editing, all authors; funding acquisition, I.P.F. and R.S.J.; supervision, M.G., M.C.W., and R.S.J.; project administration, I.P.F. and R.S.J.

DECLARATION OF INTERESTS

The authors declare no competing interests.

INCLUSION AND DIVERSITY

One or more of the authors of this paper self-identifies as a gender minority in their field of research.

Received: September 19, 2022

Revised: June 18, 2023

Accepted: August 7, 2023

Published: August 24, 2023

REFERENCES

- Minogue, E., Cunha, P.P., Quaranta, A., Zurita, J., Teli, S.S., Wadsworth, B.J., et al. (2022). Glutarate regulates T cell function and metabolism. Preprint at bioRxiv. <https://doi.org/10.1101/2022.10.20.513065>.
- Du, X., and Hu, H. (2021). The Roles of 2-Hydroxyglutarate. *Front. Cell Dev. Biol.* 9, 651317. <https://doi.org/10.3389/fcell.2021.651317>.
- Fitzpatrick, S.F., Lambden, S., Macias, D., Puthuchery, Z., Pietsch, S., Mendil, L., McPhail, M.J.W., and Johnson, R.S. (2020). 2-Hydroxyglutarate Metabolism Is Altered in an in vivo Model of LPS Induced Endotoxemia. *Front. Physiol.* 11, 147. <https://doi.org/10.3389/fphys.2020.00147>.
- Strain, S.K., Groves, M.D., Olino, K.L., and Emmett, M.R. (2020). Measurement of 2-hydroxyglutarate enantiomers in serum by chiral gas chromatography-tandem mass spectrometry and its application as a biomarker for IDH mutant gliomas. *Clin. Mass Spectrom.* 15, 16–24. <https://doi.org/10.1016/j.clinms.2019.11.002>.
- Mardis, E.R., Ding, L., Dooling, D.J., Larson, D.E., McLellan, M.D., Chen, K., Koboldt, D.C., Fulton, R.S., Delehaunty, K.D., McGrath, S.D., et al. (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. *N. Engl. J. Med.* 361, 1058–1066. <https://doi.org/10.1056/NEJMoa0903840>.
- Parsons, D.W., Jones, S., Zhang, X., Lin, J.C.H., Leary, R.J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.M., Gallia, G.L., et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. *Science* 321, 1807–1812. <https://doi.org/10.1126/science.1164382>.
- Yan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G.J., et al. (2009). IDH1 and IDH2 mutations in gliomas. *N. Engl. J. Med.* 360, 765–773. <https://doi.org/10.1056/NEJMoa0808710>.
- Fan, J., Teng, X., Liu, L., Mattaini, K.R., Looper, R.E., Vander Heiden, M.G., and Rabinowitz, J.D. (2015). Human phosphoglycerate dehydrogenase produces the oncometabolite D-2-hydroxyglutarate. *ACS Chem. Biol.* 10, 510–516. <https://doi.org/10.1021/cb500683c>.
- Intlekofer, A.M., Wang, B., Liu, H., Shah, H., Carmona-Fontaine, C., Rustenburg, A.S., Salah, S., Gunner, M.R., Chodera, J.D., Cross, J.R., and Thompson, C.B. (2017). L-2-Hydroxyglutarate production arises from noncanonical enzyme function at acidic pH. *Nat. Chem. Biol.* 13, 494–500. <https://doi.org/10.1038/nchembio.2307>.
- Intlekofer, A.M., Dematteo, R.G., Venneti, S., Finley, L.W.S., Lu, C., Judkins, A.R., Rustenburg, A.S., Grinaway, P.B., Chodera, J.D., Cross, J.R., and Thompson, C.B. (2015). Hypoxia Induces Production of L-2-Hydroxyglutarate. *Cell Metabol.* 22, 304–311. <https://doi.org/10.1016/j.cmet.2015.06.023>.
- Tyrakis, P.A., Palazon, A., Macias, D., Lee, K.L., Phan, A.T., Veliça, P., You, J., Chia, G.S., Sim, J., Doedens, A., et al. (2016). S-2-hydroxyglutarate regulates CD8(+) T-lymphocyte fate. *Nature* 540, 236–241. <https://doi.org/10.1038/nature20165>.
- Shim, E.H., Livi, C.B., Rakheja, D., Tan, J., Benson, D., Parekh, V., Kho, E.Y., Ghosh, A.P., Kirkman, R., Velu, S., et al. (2014). L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. *Cancer Discov.* 4, 1290–1298. <https://doi.org/10.1158/2159-8290.CD-13-0696>.
- Gupta, V.K., Sharma, N.S., Durden, B., Garrido, V.T., Kesh, K., Edwards, D., Wang, D., Myer, C., Mateo-Victoriano, B., Kollala, S.S., et al. (2021). Hypoxia-Driven Oncometabolite L-2HG Maintains Stemness-Differentiation Balance and Facilitates Immune Evasion in Pancreatic Cancer. *Cancer Res.* 81, 4001–4013. <https://doi.org/10.1158/0008-5472.CAN-20-2562>.
- Eckel-Passow, J.E., Lachance, D.H., Molinaro, A.M., Walsh, K.M., Decker, P.A., Sicotte, H., Pekmezci, M., Rice, T., Kosel, M.L., Smirnov, I.V., et al. (2015). Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. *N. Engl. J. Med.* 372, 2499–2508. <https://doi.org/10.1056/NEJMoa1407279>.
- Patel, J.P., Gönen, M., Figueroa, M.E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012). Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *N. Engl. J. Med.* 366, 1079–1089. <https://doi.org/10.1056/NEJMoa1112304>.
- Chou, W.C., Lei, W.C., Ko, B.S., Hou, H.A., Chen, C.Y., Tang, J.L., Yao, M., Tsay, W., Wu, S.J., Huang, S.Y., et al. (2011). The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. *Leukemia* 25, 246–253. <https://doi.org/10.1038/leu.2010.267>.
- Foskolou, I.P., Barbieri, L., Vernet, A., Bargiela, D., Cunha, P.P., Velica, P., Suh, E., Pietsch, S., Matuleviciute, R., Rundqvist, H., et al. (2020). The S enantiomer of 2-hydroxyglutarate increases central memory CD8 populations and improves CAR-T therapy outcome. *Blood Adv.* 4, 4483–4493. <https://doi.org/10.1182/bloodadvances.2020002309>.
- Yang, Q., Hao, J., Chi, M., Wang, Y., Li, J., Huang, J., Zhang, J., Zhang, M., Lu, J., Zhou, S., et al. (2022). D2HGDH-mediated D2HG catabolism enhances the anti-tumor activities of CAR-T cells in an immunosuppressive microenvironment. *Mol. Ther.* 30, 1188–1200. <https://doi.org/10.1016/j.ymthe.2022.01.007>.
- Notarangelo, G., Spinelli, J.B., Perez, E.M., Baker, G.J., Kurmi, K., Elia, I., Stopka, S.A., Baquer, G., Lin, J.R., Golby, A.J., et al. (2022). Oncometabolite d-2HG alters T cell metabolism to impair CD8(+) T cell function. *Science* 377, 1519–1529. <https://doi.org/10.1126/science.abj5104>.
- Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.H., Ito, S., Yang, C., Wang, P., Xiao, M.T., et al. (2011). Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. *Cancer Cell* 19, 17–30. <https://doi.org/10.1016/j.ccr.2010.12.014>.
- Chowdhury, R., Yeoh, K.K., Tian, Y.M., Hillringhaus, L., Bagg, E.A., Rose, N.R., Leung, I.K.H., Li, X.S., Woon, E.C.Y., Yang, M., et al. (2011). The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. *EMBO Rep.* 12, 463–469. <https://doi.org/10.1038/embor.2011.43>.
- Sallusto, F., Lenig, D., Förster, R., Lipp, M., and Lanzavecchia, A. (1999). Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature* 401, 708–712. <https://doi.org/10.1038/44385>.
- Mackay, C.R., Marston, W.L., Dudler, L., Spertini, O., Tedder, T.F., and Hein, W.R. (1992). Tissue-specific migration pathways by phenotypically distinct subpopulations of memory T cells. *Eur. J. Immunol.* 22, 887–895. <https://doi.org/10.1002/eji.1830220402>.
- Debes, G.F., Arnold, C.N., Young, A.J., Krautwald, S., Lipp, M., Hay, J.B., and Butcher, E.C. (2005). Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. *Nat. Immunol.* 6, 889–894. <https://doi.org/10.1038/ni1238>.
- Bernardi, C., Maurer, G., Ye, T., Marchal, P., Jost, B., Wissler, M., Maurer, U., Kastner, P., Chan, S., and Charvet, C. (2021). CD4(+) T cells require Ikaros to inhibit their differentiation toward a pathogenic cell fate. *Proc. Natl. Acad. Sci. USA* 118, e2023172118. <https://doi.org/10.1073/pnas.2023172118>.
- Dyson, N. (1998). The regulation of E2F by pRB-family proteins. *Genes Dev.* 12, 2245–2262. <https://doi.org/10.1101/gad.12.15.2245>.

27. van Mierlo, G., Veenstra, G.J.C., Vermeulen, M., and Marks, H. (2019). The Complexity of PRC2 Subcomplexes. *Trends Cell Biol.* *29*, 660–671. <https://doi.org/10.1016/j.tcb.2019.05.004>.
28. Gray, S.M., Amezquita, R.A., Guan, T., Kleinstein, S.H., and Kaech, S.M. (2017). Polycomb Repressive Complex 2-Mediated Chromatin Repression Guides Effector CD8(+) T Cell Terminal Differentiation and Loss of Multipotency. *Immunity* *46*, 596–608. <https://doi.org/10.1016/j.immuni.2017.03.012>.
29. Correa, L.O., Jordan, M.S., and Carty, S.A. (2020). DNA Methylation in T-Cell Development and Differentiation. *Crit. Rev. Immunol.* *40*, 135–156. <https://doi.org/10.1615/CritRevImmunol.2020033728>.
30. Matuleviciute, R., Cunha, P.P., Johnson, R.S., and Foskolou, I.P. (2021). Oxygen regulation of TET enzymes. *FEBS J.* *288*, 7143–7161. <https://doi.org/10.1111/febs.15695>.
31. Tahiliani, M., Koh, K.P., Shen, Y., Pastor, W.A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L.M., Liu, D.R., Aravind, L., and Rao, A. (2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. *Science* *324*, 930–935. <https://doi.org/10.1126/science.1170116>.
32. Domene, C., Jorgensen, C., and Schofield, C.J. (2020). Mechanism of Molecular Oxygen Diffusion in a Hypoxia-Sensing Prolyl Hydroxylase Using Multiscale Simulation. *J. Am. Chem. Soc.* *142*, 2253–2263. <https://doi.org/10.1021/jacs.9b09236>.
33. McBrayer, S.K., Mayers, J.R., DiNatale, G.J., Shi, D.D., Khanal, J., Chakraborty, A.A., Sarosiek, K.A., Briggs, K.J., Robbins, A.K., Sewastianik, T., et al. (2018). Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. *Cell* *175*, 101–116.e25. <https://doi.org/10.1016/j.cell.2018.08.038>.
34. Schenkel, L.C., and Bakovic, M. (2014). Formation and regulation of mitochondrial membranes. *Int. J. Cell Biol.* *2014*, 709828. <https://doi.org/10.1155/2014/709828>.
35. Corrado, M., Edwards-Hicks, J., Villa, M., Flachsmann, L.J., Sanin, D.E., Jacobs, M., Baixauli, F., Stanczak, M., Anderson, E., Azuma, M., et al. (2020). Dynamic Cardiolipin Synthesis Is Required for CD8(+) T Cell Immunity. *Cell Metabol.* *32*, 981–995.e7. <https://doi.org/10.1016/j.cmet.2020.11.003>.
36. Salerno, F., Guislain, A., Freen-Van Heeren, J.J., Nicolet, B.P., Young, H.A., and Wolkers, M.C. (2019). Critical role of post-transcriptional regulation for IFN-gamma in tumor-infiltrating T cells. *Oncology* *8*, e1532762. <https://doi.org/10.1080/2162402X.2018.1532762>.
37. Bunse, L., Pusch, S., Bunse, T., Sahm, F., Sanghvi, K., Friedrich, M., Alan-sary, D., Sonner, J.K., Green, E., Deumelandt, K., et al. (2018). Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. *Nat. Med.* *24*, 1192–1203. <https://doi.org/10.1038/s41591-018-0095-6>.
38. Böttcher, M., Renner, K., Berger, R., Mentz, K., Thomas, S., Cardenas-Conejo, Z.E., Dettmer, K., Oefner, P.J., Mackensen, A., Kreutz, M., and Mougiakakos, D. (2018). D-2-hydroxyglutarate interferes with HIF-1alpha stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization. *Oncology* *7*, e1445454. <https://doi.org/10.1080/2162402X.2018.1445454>.
39. Zhang, L., Sorensen, M.D., Kristensen, B.W., Reifemberger, G., McIntyre, T.M., and Lin, F. (2018). D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells. *Clin. Cancer Res.* *24*, 5381–5391. <https://doi.org/10.1158/1078-0432.CCR-17-3855>.
40. Chuntova, P., Yamamichi, A., Chen, T., Narayanaswamy, R., Ronseaux, S., Hudson, C., Tron, A.E., Hyer, M.L., Montoya, M., Mende, A.L., et al. (2022). Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma. *J. Immunother. Cancer* *10*, e004644. <https://doi.org/10.1136/jitc-2022-004644>.
41. Wu, M.J., Shi, L., Dubrot, J., Merritt, J., Vijay, V., Wei, T.Y., Kessler, E., Olander, K.E., Adil, R., Pankaj, A., et al. (2022). Mutant IDH Inhibits IFN-gamma-TET2 Signaling to Promote Immune Evasion and Tumor Maintenance in Cholangiocarcinoma. *Cancer Discov.* *12*, 812–835. <https://doi.org/10.1158/2159-8290.CD-21-1077>.
42. Kadiyala, P., Carney, S.V., Gauss, J.C., Garcia-Fabiani, M.B., Haase, S., Alghamri, M.S., Núñez, F.J., Liu, Y., Yu, M., Taher, A., et al. (2021). Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. *J. Clin. Invest.* *131*, e139542. <https://doi.org/10.1172/JCI139542>.
43. Mak, T.W., Grusdat, M., Duncan, G.S., Dostert, C., Nonnenmacher, Y., Cox, M., Binsfeld, C., Hao, Z., Brüstle, A., Itsumi, M., et al. (2017). Glutathione Primes T Cell Metabolism for Inflammation. *Immunity* *46*, 675–689. <https://doi.org/10.1016/j.immuni.2017.03.019>.
44. Hope, H.C., and Salmond, R.J. (2021). The Role of Non-essential Amino Acids in T Cell Function and Anti-tumour Immunity. *Arch. Immunol. Ther. Exp.* *69*, 29. <https://doi.org/10.1007/s00005-021-00633-6>.
45. Veliça, P., Cunha, P.P., Vojnovic, N., Foskolou, I.P., Bargiela, D., Gojkovic, M., Rundqvist, H., and Johnson, R.S. (2021). Modified Hypoxia-Inducible Factor Expression in CD8(+) T Cells Increases Antitumor Efficacy. *Cancer Immunol. Res.* *9*, 401–414. <https://doi.org/10.1158/2326-6066.CIR-20-0561>.
46. de Witte, M.A., Coccoris, M., Wolkers, M.C., van den Boom, M.D., Mesman, E.M., Song, J.Y., van der Valk, M., Haanen, J.B.A.G., and Schumacher, T.N.M. (2006). Targeting self-antigens through allogeneic TCR gene transfer. *Blood* *108*, 870–877. <https://doi.org/10.1182/blood-2005-08-009357>.
47. van Stipdonk, M.J.B., Hardenberg, G., Bijker, M.S., Lemmens, E.E., Droin, N.M., Green, D.R., and Schoenberger, S.P. (2003). Dynamic programming of CD8+ T lymphocyte responses. *Nat. Immunol.* *4*, 361–365. <https://doi.org/10.1038/ni912>.
48. Popović, B., Nicolet, B.P., Guislain, A., Engels, S., Jurgens, A.P., Paravinja, N., Freen-van Heeren, J.J., van Alphen, F.P.J., van den Biggelaar, M., Salerno, F., and Wolkers, M.C. (2023). Time-dependent regulation of cytokine production by RNA binding proteins defines T cell effector function. *Cell Rep.* *42*, 112419. <https://doi.org/10.1016/j.celrep.2023.112419>.
49. Brooks, B.R., Brooks, C.L., 3rd, Mackerell, A.D., Jr., Nilsson, L., Petrella, R.J., Roux, B., Won, Y., Archontis, G., Bartels, C., Boresch, S., et al. (2009). CHARMM: the biomolecular simulation program. *J. Comput. Chem.* *30*, 1545–1614. <https://doi.org/10.1002/jcc.21287>.
50. Fletcher, R., and Reeves, C.M. (1964). Function minimization by conjugate gradients. *Comput. J.* *7*, 149–154.
51. Lemons, D.S., and Gythiel, A. (1997). Paul Langevin's 1908 paper "On the Theory of Brownian Motion" ["Sur la théorie du mouvement brownien." *C. R. Acad. Sci. (Paris)* *146*, 530–533 (1908)]. *Am. J. Phys.* *65*, 1079–1081. <https://doi.org/10.1119/1.18725>.
52. Karplus, M., and Petsko, G.A. (1990). Molecular dynamics simulations in biology. *Nature* *347*, 631–639. <https://doi.org/10.1038/347631a0>.
53. Warshel, A. (2002). Molecular dynamics simulations of biological reactions. *Acc. Chem. Res.* *35*, 385–395. <https://doi.org/10.1021/ar010033z>.
54. Tuckerman, M., Berne, B.J., and Martyna, G.J. (1992). Reversible multiple time scale molecular dynamics. *J. Chem. Phys.* *97*, 1990–2001. <https://doi.org/10.1063/1.463137>.
55. Phillips, J.C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R.D., Kalé, L., and Schulten, K. (2005). Scalable molecular dynamics with NAMD. *J. Comput. Chem.* *26*, 1781–1802. <https://doi.org/10.1002/jcc.20289>.
56. Nosé, S. (1984). A molecular dynamics method for simulations in the canonical ensemble. *Mol. Phys.* *52*, 255–268. <https://doi.org/10.1080/00268978400101201>.
57. Nosé, S. (1984). A unified formulation of the constant temperature molecular dynamics methods. *J. Chem. Phys.* *81*, 511–519. <https://doi.org/10.1063/1.447334>.
58. Darden, T., York, D., and Pedersen, L. (1993). Particle mesh Ewald: An N·log(N) method for Ewald sums in large systems. *J. Chem. Phys.* *98*, 10089–10092. <https://doi.org/10.1063/1.464397>.

59. Miyamoto, S., and Kollman, P.A. (1992). Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models. *J. Comput. Chem.* *13*, 952–962. <https://doi.org/10.1002/jcc.540130805>.
60. Love, M.I., Hogenesch, J.B., and Irizarry, R.A. (2016). Modeling of RNA-seq fragment sequence bias reduces systematic errors in transcript abundance estimation. *Nat. Biotechnol.* *34*, 1287–1291. <https://doi.org/10.1038/nbt.3682>.
61. Cunningham, F., Allen, J.E., Allen, J., Alvarez-Jarreta, J., Amode, M.R., Armean, I.M., Austine-Orimoloye, O., Azov, A.G., Barnes, I., Bennett, R., et al. (2022). Ensembl 2022. *Nucleic Acids Res.* *50*, D988–D995. <https://doi.org/10.1093/nar/gkab1049>.
62. Kuleshov, M.V., Jones, M.R., Rouillard, A.D., Fernandez, N.F., Duan, Q., Wang, Z., Koplev, S., Jenkins, S.L., Jagodnik, K.M., Lachmann, A., et al. (2016). Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res.* *44*, W90–W97. <https://doi.org/10.1093/nar/gkw377>.
63. Monaco, G., Lee, B., Xu, W., Mustafah, S., Hwang, Y.Y., Carré, C., Burdin, N., Visan, L., Ceccarelli, M., Poidinger, M., et al. (2019). RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types. *Cell Rep.* *26*, 1627–1640.e7. <https://doi.org/10.1016/j.celrep.2019.01.041>.
64. Bernardo-Bermejo, S., Xue, J., Hoang, L., Billings, E., Webb, B., Honders, M.W., Venneker, S., Heijs, B., Castro-Puyana, M., Marina, M.L., et al. (2023). Quantitative multiple fragment monitoring with enhanced in-source fragmentation/annotation mass spectrometry. *Nat. Protoc.* *18*, 1296–1315. <https://doi.org/10.1038/s41596-023-00803-0>.
65. Kostidis, S., Addie, R.D., Morreau, H., Mayboroda, O.A., and Giera, M. (2017). Quantitative NMR analysis of intra- and extracellular metabolism of mammalian cells: A tutorial. *Anal. Chim. Acta* *980*, 1–24. <https://doi.org/10.1016/j.aca.2017.05.011>.
66. Wigle, T.J., Swinger, K.K., Campbell, J.E., Scholle, M.D., Sherrill, J., Admirand, E.A., Boriack-Sjodin, P.A., Kuntz, K.W., Chesworth, R., Moyer, M.P., et al. (2015). A High-Throughput Mass Spectrometry Assay Coupled with Redox Activity Testing Reduces Artifacts and False Positives in Lysine Demethylase Screening. *J. Biomol. Screen* *20*, 810–820. <https://doi.org/10.1177/1087057115575689>.
67. Jorgensen, W.L., Chandrasekhar, J., Madura, J.D., Impey, R.W., and Klein, M.L. (1983). Comparison of simple potential functions for simulating liquid water. *J. Chem. Phys.* *79*, 926–935. <https://doi.org/10.1063/1.445869>.
68. Vanommeslaeghe, K., and MacKerell, A.D., Jr. (2012). Automation of the CHARMM General Force Field (CGenFF) I: Bond Perception and Atom Typing. *J. Chem. Inf. Model.* *52*, 3144–3154. <https://doi.org/10.1021/ci300363c>.
69. Rostkowski, M., Olsson, M.H.M., Søndergaard, C.R., and Jensen, J.H. (2011). Graphical analysis of pH-dependent properties of proteins predicted using PROPKA. *BMC Struct. Biol.* *11*, 6. <https://doi.org/10.1186/1472-6807-11-6>.
70. Verlet, L. (1967). Computer "Experiments" on Classical Fluids. I. Thermodynamical Properties of Lennard-Jones Molecules. *Phys. Rev.* *159*, 98–103. <https://doi.org/10.1103/PhysRev.159.98>.

STAR★METHODS

KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|----------------------------|--|
| Antibodies | | |
| 5-Hydroxymethylcytosine; <i>In vitro</i> assay & Flow cytometry | Active Motif | 39999; RRID:AB_2566808 |
| CCR7 (human); Flow cytometry | BD Biosciences | 3D12; RRID:AB_2033950 & RRID:AB_396765 |
| CD107a (mouse); Flow cytometry | eBiosciences | ID4B; RRID:AB_657536 |
| CD127 (mouse); Flow cytometry | Biolegend | A7R34; RRID:AB_1937252 |
| CD25 (mouse); Flow cytometry | eBiosciences | PC61.5; RRID:AB_10671550 |
| CD28 (human); Flow cytometry | Biolegend | CD28.2; RRID:AB_2936698 & RRID:AB_528785 |
| CD44 (mouse); Flow cytometry | Biolegend | IM7; RRID:AB_830786 & RRID:AB_312962 |
| CD45.1 (mouse); Flow cytometry | Biolegend & BD Biosciences | A20; RRID:AB_313494; RRID:AB_1134170 & RRID:AB_2738523 |
| CD45.2 (mouse); Flow cytometry | Biolegend | 104; RRID:AB_893352 & RRID:AB_492871 |
| CD45RO (human); Flow cytometry | Biolegend | UCHL1; RRID:AB_2562143 & RRID:AB_2616917 |
| CD62L (human); Flow cytometry | Biolegend | DREG-56; RRID:AB_528857; RRID:AB_493583; RRID:AB_314463 & RRID:AB_893396 |
| CD62L (mouse); Flow cytometry | Biolegend | MEL-14; RRID:AB_313094 & RRID:AB_313092 |
| CD8a (human); Flow cytometry | Biolegend & BD Biosciences | HIT8a; RRID:AB_528884 & SK1; RRID:AB_2722546 |
| CD8a (mouse); Flow cytometry | BD Biosciences | 53-6.7; RRID:AB_2732919 |
| CTLA-4 (mouse); Flow cytometry | Biolegend | UC10-4B9; RRID:AB_313254 |
| Dynabeads human T-activator CD3/CD28 | Gibco | 11132D; RRID:AB_2943359 |
| FcR Block | MACS Miltenyi | 120-000-826; RRID:AB_2943360 |
| GzmB (mouse); Flow cytometry | Biolegend | AD2; RRID:AB_2228785 |
| GzmB (mouse); Flow cytometry | BD Biosciences | GB11; RRID:AB_10561690 |
| H3K27Ac (human); Western Blot | Cell Signaling | 8173; RRID:AB_10949503 |
| H3K27me3 (human); Western Blot | Cell Signaling | 9733; RRID:AB_2616029 |
| H3K9Ac (human); Western Blot | Cell Signaling | 9649; RRID:AB_823528 |
| H3K9me2 (human); Western Blot | Cell Signaling | 4658; RRID:AB_10544405 |
| H3K9me3 (human); Western Blot | Cell Signaling | 13969; RRID:AB_2798355 |
| Histone3 (H3) (human); Western Blot | Cell Signaling | 4499; RRID:AB_10544537 |
| HRP-conjugated secondary antibodies; Western Blot | R&D | HAF008; RRID:AB_357235 & HAF007; RRID:AB_357234 |
| ICOS (mouse); Flow cytometry | Biolegend | C398.4A; RRID:AB_10639735 |
| IFN- γ (mouse); Flow cytometry | Biolegend | XMG1.2; RRID:AB_315401 |
| IL-2 (mouse); Flow cytometry | eBiosciences | JES6-5H4; RRID:AB_469490 |
| Ki67 (mouse); Flow cytometry | eBiosciences | SoIA15; RRID:AB_2637480 |
| Ki67 (mouse); Flow cytometry | BD Biosciences | B56; RRID:AB_10611571 |

(Continued on next page)

Continued

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Mab anti-histone H3K9 Me2-Eu(K) antibody; <i>In vitro</i> assay | Cisbio | 61KB2KAE; RRID:AB_2943356 |
| PD-1 (human); Flow cytometry | Biolegend | EH12.2H7; RRID:AB_2563593 & RRID:AB_11124107 |
| PD-1 (mouse); Flow cytometry | BD Biosciences | J43; RRID:AB_2742319 |
| Streptavidin-Alexa Fluor 647; <i>In vitro</i> assay | Life Technologies | S21374 |
| TNF- α (mouse); Flow cytometry | Biolegend | MP6-XT22; RRID:AB_10900823 |
| TOX (human); Flow cytometry | Fisher Scientific | TXRX10; RRID:AB_2574265 |
| XL665-conjugated Streptavidin; <i>In vitro</i> assay | Cisbio | 610SAXLA |
| Biological samples | | |
| Peripheral blood mononuclear cells (PBMCs) were obtained from healthy donors with consent | Cambridge Bioscience; National Health Service (NHS) Blood and Transplant (NHSBT: Addenbrooke's Hospital, Cambridge, UK); Sanquin Blood bank (Amsterdam, NL) | N/A |
| Chemicals, peptides, and recombinant proteins | | |
| 4-Pyridine dicarboxylic acid | Sigma | 04473 |
| Ammonium iron(II) sulfate hexahydrate | Sigma | F3754 |
| BD CellFIX | BD Biosciences | 340181 |
| Bovine liver catalase | Sigma | C40 |
| Brefeldin A | Invitrogen | 00-4506-51 |
| BSA | Sigma | B2064 |
| Collagenase | Worthington Biochemical | 9001-12-1 |
| CountBright™ Absolute Counting Beads | Life Technologies | C36950 |
| Cyclophosphamide | Sigma | C0768 |
| D- α -Hydroxyglutaric acid disodium salt (R-2HG – <i>in vitro</i> assays) | Sigma | H8378 |
| Disodium DL-2-hydroxyglutarate-d3 | CDN isotopes | D-7496 |
| DNase I (recombinant) | Roche | 09852093103 |
| ECL | Sigma | GERPN2106 |
| EDTA | Ambion | AM9260G |
| EDTA | Sigma | 0369 |
| Europium Protein A | Cisbio | 61PRAKLB |
| Ficoll-Paque PLUS density gradient separation | GE Healthcare | 71-7167-00 AF |
| H3K9(Me3)-GGK(Biotin), peptide | Anaspec | AS-64360-1 |
| HEPES | Gibco | 15630-080 |
| HTRF Detection Buffer | Cisbio | 61DB9RDF |
| Human IL-2 (recombinant) | Roche | 11 011 456 001 |
| Human IL-2 (recombinant) (Proleukin, Aldesleukin) | Clinigen | N/A |
| Human KDM4C recombinant peptide | BPS Bioscience | 50105 |
| Human TET2 recombinant peptide | BPS Bioscience | 50162 |
| L-Ascorbic acid | Sigma | A5960 |
| L-DATAN | Sigma | 358924 |
| L- α -Hydroxyglutaric acid disodium salt (S-2HG – <i>in vitro</i> assays) | Sigma | 90790 |
| LC-MS-grade acetic acid $\geq 99\%$ | Sigma | A6283 |
| LC-MS-grade acetonitrile | Honeywell | 34967 |
| LC-MS-grade methanol | Supelco | 1.06035.2500 |
| LC-MS-grade water | Honeywell | 14263 |
| Live/Dead Fixable Viability Dyes | Invitrogen | L34963 & L10119 |

(Continued on next page)

Continued

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|--|----------------|
| Monensin | eBioscience | 00-4505-51 |
| N-Oxalylglycine | Sigma | O9390 |
| OneComp eBeads | Invitrogen | 01-1111-42 |
| OVA ₂₅₇₋₂₆₄ peptide | GenScript | RP10611 |
| Pluronic F-127 | PromoCell | PK-CA707-59005 |
| R-2-HG octyl ester Na salt C ₁₃ H ₂₃ NaO ₅ ((2R)-2-Hydroxyglutaric Acid Octyl Ester Sodium Salt) CAS ID: 1391068-16-8 | Toronto Research Chemicals | H942595 |
| S-2-HG octyl ester Na salt C ₁₃ H ₂₃ NaO ₅ ((2S)-2-Hydroxyglutaric Acid Octyl Ester Sodium Salt) CAS ID: 1391067-96-1 | Toronto Research Chemicals | H942596 |
| SIINFEKL | Prolimmune | P093-0A-G |
| TCEP | Shanghai Yuanye Bio-Technology Company | S16054 |
| Trimethylsilyl propionic-d4-sodium salt (TSP-d4) | Cambridge Isotope Laboratories, Inc. | DLM-48-PK |
| α-ketoglutarate (α-KG) | Sigma | K3752 |
| β-mercaptoethanol | Thermo Fisher | 21985023 |

Critical commercial assays

| | | |
|---|----------------|-------------|
| BCA protein assay kit | Abcam | ab207003 |
| CD8 ⁺ T cell beads (mouse) | MACS Miltenyi | 130-104-075 |
| Cytofix/Cytoperm kit Fixation/Permeabilization Kit | BD Biosciences | 554714 |
| Foxp3/Transcription Factor Staining Buffer Set | eBioscience | 00-5523-00 |
| Histone Extraction Kit | Abcam | ab113476 |
| Naive CD8 ⁺ T cell isolation kit (human) | MACS Miltenyi | 130-093-244 |
| Total CD8 ⁺ T cell isolation kit (human) | MACS Miltenyi | 130-096-495 |
| True-Nuclear Transcription Factor Buffer Set | Biolegend | 424401 |

Deposited data

| | | |
|-------------------------------|---------------|---|
| Mendeley Data | Elsevier inc. | https://doi.org/10.17632/gj337xjxk6.1 |
| Gene Expression Omnibus (GEO) | NCBI | GSE212738 |

Experimental models: Cell lines

| | | |
|--|-------------------------------------|-----|
| Mouse B16-F10-OVA cells (used in the Karolinska Institute) | Veliça et al. 4 ⁴⁵ | N/A |
| Mouse B16-OVA cells (used in Sanquin) | de Witte et al. 4 ⁴⁶ | N/A |
| Mouse OVA-expressing MEC.B7.SigOVA cells | van Stipdonk et al. 4 ⁴⁷ | N/A |

Experimental models: Organisms/strains

| | | |
|---|--------------------------------|---|
| Mouse: B6.SJL-Ptprca Pepcb/BoyJ (Ly5.1) | The Jackson Laboratory | JAX:002014 |
| Mouse: C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-I) | The Jackson Laboratory | JAX:003831 |
| Mouse: C57BL/6J | Charles River | 632 |
| Mouse: C57BL/6J/Ly5.1/Ly5.2 | Popović et al. 4 ⁴⁸ | N/A |
| Mouse: C57BL/6JRj (Ly5.2) | Janvier Labs | https://www.janvier-labs.com/en/fiche_produit/c57bl-6jrj_mouse/ |

Recombinant DNA

| | | |
|--|-----------|------------------|
| ssDNA (ssBiotin 26nt HydMe-C Oligo- Standard) 5'-/5Biosg/CAGTAGTCTGGACACAC/i5HydMe-dC/GGTCATGA-3' | Genscript | Custom synthesis |
| ssDNA (ssBiotin 26nt Me-C Oligo – Substrate) /5Biosg/CAGTAGTCTGGACACAC/iMe-dC/GGTCATGA-3' | Genscript | Custom synthesis |

Software and algorithms

| | | |
|--------------|-------------------------------|---|
| CHARMM 36 FF | Brooks et al. 4 ⁴⁹ | N/A |
| CHARMM-GUI | Lehigh University, Bethlehem | https://www.charmm-gui.org |

(Continued on next page)

Continued

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|----------------------------------|--|---|
| Conjugate-Gradient minimization | Fletcher and Reeves 5 ⁵⁰ | N/A |
| FlowJo v10 | BD Biosciences | https://www.flowjo.com/ |
| GraphPad Prism v9.5.1 | GraphPad Software | https://www.graphpad.com/ |
| Langevin thermostat | Lemons and Gythiel 5 ⁵¹ | N/A |
| Molecular Dynamics | Karplus and Petsko; Warshel 5 ^{52,53} | N/A |
| Multi time step Verlet-l/r-RESPA | Tuckerman et al. 5 ⁵⁴ | N/A |
| NAMD 2.9 | Phillips et al. 5 ⁵⁵ | N/A |
| Nosé-Hoover Langevin piston | Nosé 5 ^{56,57} | N/A |
| Particle Mesh Ewald (PME) | Darden et al. 5 ⁵⁸ | N/A |
| SETTLE algorithm | Miyamoto and Kollman 5 ⁵⁹ | N/A |
| Other | | |
| DMEM | Thermo Scientific | 11995065 |
| Fetal Bovine Serum (FBS) | Sigma | F7524 |
| G418 sulfate | Thermo Scientific | 10131027 |
| Penicillin and Streptomycin | Sigma | P0781 |
| RPME media | Gibco | 52400-025 |

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Randall S Johnson (rsj33@cam.ac.uk).

Materials availability

This study did not generate new unique reagents.

Data and code availability

- The RNA-Seq data generated in this study are publicly available in Gene Expression Omnibus (GEO): GSE212738. Some original and all analyzed data are publicly available in Mendeley Data: <https://doi.org/10.17632/gj337xjxk6.1>.
- Scripts/codes used in the paper are available at: <https://github.com/BenNicolet/RNA-Seq-2HG-Foskolou-et-al-2023>; <https://github.com/chrisjorg/MDscripts-RS>
- Any additional information required to reanalyze the data reported in this work paper is available from the **lead contact** upon request.

EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

Mice

C57BL/6J/Ly5.2, C57BL/6J/Ly5.1/Ly5.2 mice and C57BL/6J were bred in-house at the Netherlands Cancer Institute (NKI) or were purchased from Janvier Labs (for animal experiments performed in the Karolinska Institute, Sweden). Donor T cell receptor (TCR) transgenic mice (OT-I) mice were either crossed with mice bearing the CD45.1 congenic marker (002014, The Jackson Laboratory) for the tumor orthotopic models or with the CD45.2 congenic marker for the infiltration experiments. Experiments were performed in accordance with institutional and national guidelines and approved by the Experimental Animal Committee at the NKI and by the regional animal ethics committee of Northern Stockholm, Sweden under Ethical Permit number 5261-2020. All animals were housed in individually ventilated cage systems under specific-pathogen-free conditions. Both male and female mice were used at 8–12 weeks of age. Replicates of each experiment are described in the figure legends. The mice were randomised before the injection of the treated OT-I cells. No blinding was performed. All samples that passed the technical requirements were included (e.g., enough cells for flow cytometry).

Human and mouse T cell cultures and treatments

Peripheral blood mononuclear cells (PBMCs) were obtained from healthy donors from Cambridge Bioscience, National Health Service (NHS) Blood and Transplant (NHSBT: Addenbrooke's Hospital, Cambridge, UK) or Sanquin (Amsterdam, NL). The study was performed according to the Declaration of Helsinki (seventh revision, 2013). Ethical approval was obtained from the East of

England-Cambridge Central Research Ethics Committee (06/Q0108/281) and consent was obtained from all subjects. Written informed consent was obtained (Cambridge Bioscience, Cambridge, UK; NHSBT Cambridge, UK; Sanquin Research, Amsterdam, NL). Human CD8⁺ T cells were isolated either directly after blood donation (8–12 h after blood collection) or they were cryopreserved and used after cryopreservation. PBMCs were isolated through Ficoll-Paque PLUS density gradient separation (GE Healthcare). Cells were incubated in 21% oxygen, 5% carbon dioxide at 37°C.

Human T cell isolation was performed with MACS Miltenyi kits (Naive CD8⁺ T cells: 130-093-244 or Total CD8⁺ T cells: 130-096-495) following manufacturer's instructions. CD8⁺ T cells were activated with aCD3/CD28 beads (1:1 beads-to-cell ratio) (11132D, Gibco). OE-S-2HG treatment and OE-R-2HG (H942595; H942596 Toronto Research Chemicals) started at day 0 and was at 0.4 mM concentration, otherwise stated. Every second day, fresh complete RPMI media (52400-025; Gibco) containing 10% FBS, 1% penicillin-streptomycin and IL-2 (30 U/ml) and the appropriate amount of OE-S-2HG, OE-R-2HG or vehicle was added. Cell number and viability were measured by ADAM-MC automated cell counter (NanoEnTek) or by CASY cell counter and analyser (BIOKE). Rate of cell division was calculated by dividing the cell number of day (X+2) by cell number of day X.

Mouse splenic OT-I CD8⁺ T cell isolation was performed with MACS Miltenyi kit (CD8⁺ T cells: 130-104-075) following manufacturer's instructions. OT-I T cells were activated with either SIINFEKL (1000 ng/mL) or by co-culturing them with pre-seeded OVA-expressing MEC.B7.SigOVA cells.⁴⁷ The day after activation, the OT-I T cells were collected, washed, and treated with OE-S-2HG, OE-R-2HG or vehicle or 6–7 days. Cells were maintained in fresh complete RPMI media (52400-025; Gibco) containing 10% FCS, 1% penicillin-streptomycin, 55 μM β-mercaptoethanol and IL-2 (30 U/ml). B16-F10-OVA cells were cultured in DMEM high glucose with pyruvate (11995065 Thermo Scientific) containing 0.75 mg/mL G418 sulfate (10131027, Thermo Scientific).

METHOD DETAILS

Flow cytometry

Human CD8⁺ T cells FACS analysis was performed on day 12, otherwise stated. Mouse CD8⁺ T cells were analyzed at day 7 of culture and OT-I adoptively transferred T cells were analyzed after blood or organ/tumor harvesting. Cells were pelleted by centrifugation and stained with antibodies in FACS Buffer (5% FBS, 2 mM EDTA in PBS) at 4°C for 30–60 min. CCR7 staining was performed in media at 37°C. The stained cells were then washed with FACS buffer, pelleted, and re-suspended in 1x FACS-Fix (BD CellFIX™) and kept at 4°C in the dark until processing. The samples were processed 2–3 days after fixation. For intracellular cytokine staining, cells were cultured in the presence of 1 μg/mL brefeldin A and monensin (00-4505-51, eBioscience) for 2 h and were then fixed and permeabilized with Cytofix/Cytoperm kit (BD Biosciences) according to manufacturer's protocol. For intracellular transcription factor and proliferation staining the Foxp3/Transcription Factor Staining (eBioscience) was used. On the day of analysis, the cells were resuspended in FACS Buffer containing counting beads (CountBright™ Absolute Counting Beads). The number of cells in each sample was calculated according to the manufacturer's instructions. Emission spectra "spillover" was corrected by compensation using compensation beads (01-1111-41; OneComp eBeads) mixed with each fluorescent probe. Flow cytometers used: BD LSR-Fortessa, AttuneX (Invitrogen) and BD FACSymphony. The flow data were analyzed using FlowJo (BD Biosciences, version 10). The antibodies used can be found in the "Key resources table".

Western blots and 5hmC staining

For western blots, human naive CD8⁺ T cells were isolated from healthy donors and treated from day 0 to day 12 with OE-S-2HG (0.4 mM), OE-R-2HG (0.4 mM) or vehicle. The cells were activated with aCD3/CD28 beads for 4 days as explained above. At day 12, cells were collected, washed, lysed and the histones were extracted by using the Histone Extraction Kit (ab113476, Abcam) the manufacturer's instructions. Protein quantification was performed with the BCA protein assay kit (ab207003, Abcam). Proteins were separated by SDS-PAGE and transferred to PVDF membranes. Membranes were then blocked in 5% milk prepared in PBS with 0.05% Tween 20, incubated with primary antibodies overnight at 4°C and HRP-conjugated secondary antibodies (HAF008 and HAF007, R&D) for 1 h at room temperature the next day. Following ECL exposure (GERPN2106, Sigma), membranes were imaged using an iBrightCL1000 (Thermo Fisher). The primary antibodies used can be found in the "Key resources table".

For 5hmC staining, naive CD8⁺ T cells were isolated from healthy donors and treated from day 0 to day 7 with OE-S-2HG (0.4 mM), OE-R-2HG (0.4 mM) or vehicle. The cells were activated with aCD3/CD28 beads for 4 days as explained above. At day 7, cells were collected, washed, and stained with Live/Dead (L34963, Invitrogen) and anti-human CD8a (53-6.7, Biolegend). The cells were then fixed (30 min at room temperature in the dark) and permeabilized (30 min at room temperature in the dark) (True-Nuclear Transcription Factor kit; Biolegend). After fixation and permeabilization, the cells were incubated with 4M HCL for 10 min at room temperature. The cells were then thoroughly washed and incubated in blocking buffer (0.1% PBS-Triton, 5% FCS) for 30 min at 4°C. The cells were then incubated either with primary anti-5hmC (10013602; Active Motif) or with isotype control antibody overnight at 4°C and the day after with secondary antibody for 1 h at room temperature. Flow cytometry was then performed as explained above.

RNA-Seq analysis and GSEA

Naive CD8 T cells activated and treated with OE-S-2HG (0.4 mM), OE-R-2HG (0.4 mM) or vehicle and cells were collected on day 5 or day 12. The cells were lysed on RLT Buffer containing (1:100) β-Mercaptoethanol. RNA-Seq libraries were prepared and sequenced by Active Motif (USA) on Illumina NextSeq 500 for 42 cycles (42nt paired-end reads). Reads were quasi-mapped and quantified using

Salmon (version 1.8),⁶⁰ onto the transcriptome (ENSEMBL version 104).⁶¹ DESeq2 was used for differential expression analysis (cut-off: adjusted *p* value < 0.05 and absolute LFC > 0.5). For GSEA analysis, we used counts outputted by STAR after mapping on the genome hg38 (ENSEMBL). GSEA analysis was performed with default setting to determine gene-set enrichment based on biological knowledge (e.g., genes sharing the same GO category). GSEAPreranked tool developed by Broad Institute: (<http://software.broadinstitute.org/gsea/index.jsp>).

The OE-R-2HG upregulated significant genes were used for enrichment analysis with the EnrichR tool⁶² and the ENCODE transcription factor ChIP-Seq library. The Human Protein Atlas (proteinatlas.org) and Monaco⁶³ dataset was used to check the expression of specific genes in different immune cell types.

In vitro enzymatic activity assays

For enzymatic activity of the KDM4C enzyme, the human KDM4C enzyme (8 nM) was incubated with the substrate of H3(1–21) lysine 9 tri-methylated biotinylated peptide (30 nM), in the presence of α KG (10 μ M), ammonium iron(II) sulfate hexahydrate (5 μ M), assay buffer (50 mM HEPES pH 7.0, 0.01% Tween 20, 1mM ascorbic acid and 0.01% BSA). S-2HG (Sigma) and R-2HG (Sigma) were used in 3-fold serial dilution and the maximum concentration used was 5 mM. The pre-incubation time of the inhibitors with the KDM4C mixture was 30 min at room temperature. The reaction step was at room temperature for 210 min. The product was detected by using an anti-histone H3K9 Me2-Eu(K) antibody and XL665-conjugated Streptavidin. The detection of the homogeneous time resolved fluorescence (HTRF) signal was proportional to the concentration of demethylated H3(1–21) peptide. The assays were performed in technical duplicates in a 384-well plate and repeated 2–3 independent times. The inhibitor analysis was performed within the linear range of catalysis.

For enzymatic activity of the TET2 enzyme, the human TET2 enzyme (2 nM) was incubated with the substrate of ssDNA (ssBiotin 26nt Me-C Oligo 30 nM), in the presence of α KG (115 μ M), ammonium iron(II) sulfate hexahydrate (10 μ M), in assay buffer (50 mM HEPES pH 7.0, 100 mM NaCl, 0.01% Pluronic F-127, 1mM TCEP, 2mM ascorbic acid, 0.2 mg/mL BSA and 1000U/ml Catalase). S-2HG (Sigma) and R-2HG (Sigma) were used in 3-fold serial dilution and the maximum concentration used was 5 mM. The pre-incubation time of the inhibitors with the TET2 mixture was 30 min at room temperature. The reaction step was at room temperature for 90 min. The product was detected by using an anti-5-Hydroxymethylcytosine antibody (5 nM), Eu-Protein A (5 nM), Streptavidin-Alexa Fluor 647 (6.25 nM) and 10 mM EDTA. For the standard curve, the ssBiotin 26nt HydMe-C Oligo was used. The assays were performed in technical duplicates in a 384-well plate and repeated 2–3 independent times. The inhibitor analysis was performed within the linear range of catalysis.

The percentage of inhibition was calculated with the following formula: Inhibition% = $(1 - (\text{signal value per well} - \text{Average Low control}) / (\text{Average High control} - \text{Average Low control})) * 100$. The data were fitted by Prism Graphpad with four parameters equation via "log(inhibitor) vs. response – Variable slope" model.

Quantification of R- and S-2HG by LC-MS

Pelleted T-cells were extracted in 200 μ L of ice-cold 80% (v/v) methanol in water were added to the cell pellets. 2 μ L of a 1 mM (RS)-2HG- d_3 deuterated internal standard (IS) was added at this step to correct for possible losses during the sample preparation and for matrix effects, as well as aiding in the correct annotation of 2HG enantiomers. Samples were sonicated for 1 min and kept at -20°C for 30 min to allow for protein precipitation. After centrifugation at 18000xg and 4°C for 10 min supernatants were transferred to new 1.5 mL Eppendorf tubes. Extraction was repeated with 100 μ L 80% (v/v) methanol and supernatants were combined. Samples were dried using a SpeedVac (Eppendorf) until fully dry.⁶⁴

Derivatization of the dried pellets took place by adding 50 μ L of 50 mg/mL L-DATAN in 4:1 (v/v) acetonitrile:acetic acid to form the corresponding 2HG-DATAN diastereomers that can be separated under achiral chromatographic conditions. To favor the derivatization, samples were placed in a heat block for 2 h at 80°C after which they were briefly spun down and fully dried under nitrogen gas stream. After reconstitution with 100 μ L 4:1 (v/v) water:acetic acid the samples were transferred to glass inserts, placed in LC vials and were subjected to LC-MS analysis. Similarly, a calibration line was constructed using R- and S-2HG standard solutions having a final concentration from 0.5 to 200 μ M of each enantiomer. Each calibration line solution was spiked with the same amount of IS than for the samples and were likewise derivatized and analyzed.

All the samples and calibration line solutions were analyzed by liquid chromatography coupled to mass spectrometry (LC-MS) using so-called enhanced in-source fragmentation to enable MS fragmentation.⁶⁴ The analyses were conducted in an ultra-high-performance LC Dionex UltiMate 3000 UHPLC (Thermo Fisher) system coupled to a Bruker Impact II Q-TOF system (Bruker) provided with a Develosil Aqua C30 column (3 μ m; 2 mm inner diameter (i.d.) \times 150 mm length) and a Phenomenex C8 2.1 mm i.d. precolumn. LC eluents were pumped at a 0.4 mL/min flow rate having as mobile phase A 125 mg/L of ammonium formate in water (pH 3.6) and as mobile phase B 95% (v/v) of acetonitrile in water. The chromatographic gradient composition was 0% B at 0.0 min, 36% B at 5.0 min, 100% B at 6.0 min, 100% B at 8.0 min, 0% B at 8.4 min and 0% B at 13.0 min. S- and R-2HG as well as their respective enantiomeric deuterated versions (IS) eluted at 3.7 and 3.9 min, respectively, and were monitored using the ions *m/z* 363.0570 + 147.0270 (for 2HG) and *m/z* 366.0745 + 150.0491 (for the deuterated 2HG IS).

NMR-based metabolomics

Sample preparation for the quantification of metabolites by nuclear magnetic resonance (NMR) spectroscopy cells were washed once with PBS, centrifuged and quenched in liquid nitrogen.⁶⁵ Polar metabolites were extracted with 200 μ L of an ice-cold solution of 67.5:7.5:25 (v/v/v) of methanol/chloroform/water at -20°C . Samples were sonicated for 1 min, were kept on dry-ice for 30 min and were further centrifuged at 18,000 \times g for 15 min at 4°C . The supernatant was collected and fully dried under nitrogen gas stream. Samples were reconstituted in 220 μ L of a 50 mM phosphate buffer (pH 7.4) solution in deuterated water containing 0.05 mM trimethylsilyl propionic- d_4 -sodium salt (TSP- d_4 , Cambridge Isotope Laboratories, Inc.) as internal standard used for NMR referencing and quantification. One NMR experiment (pulse sequence: *noesygppr1d*; Bruker Biospin Ltd) was collected for each sample in a 14.1 T (600 MHz for ^1H) Bruker Avance Neo NMR. All recorded NMR spectra were imported in Chenomx NMR suite 9.0 (Chenomx NMR suite, v9.0, Edmonton, AB, Canada) for the quantification of metabolites. Quantitative data (pmoles) was then normalized to the number of cells of each sample.

Simulations

System setup: The atomic structure of the KDM4C protein (PDB id 4XDO; resolution 1.97 \AA)⁶⁶ in complex with α KG (KDM4C: α KG:Fe(II)) was used as a starting point for Molecular Dynamics (MD) simulations. Three systems were prepared: KDM4C: α KG:Fe(II), KDM4C:2HG-(S):Fe(II) and KDM4C:2HG-(R):Fe(II). Calculations were done with NAMD 2.9,⁵⁵ using the CHARMM 36 protein force-field⁴⁹ together with the TIP3P water model.⁶⁷ 2OG, 2HG-(S), and 2HG-(R) parameters were obtained in CHARMM from Paramchem.⁶⁸ Fe(II) Lennard Jones parameters were taken from the CHARMM force field. Default ionization states were used for the protein on the basis of PropKa calculations.⁶⁹

Simulation details: The particle mesh Ewald (PME) algorithm was used for the evaluation of electrostatic interactions beyond 12 \AA , with a PME grid spacing of 1 \AA , and NAMD defaults for spline and κ values.⁵⁸ A cutoff at 12 \AA was applied to nonbonded forces. Both electrostatics and van der Waals forces were smoothly switched off between the cutoff distance of 12 \AA and the switching distance of 10 \AA using the default NAMD switching function. A Verlet neighbor list⁷⁰ with pairlist distance of 14 \AA was used only to evaluate nonbonded neighboring forces within the pairlist distance. The lengths of covalent bonds involving hydrogen atoms were constrained by the SETTLE algorithm⁵⁹ to be able to use a 2 fs timestep. The multi time step algorithm Verlet-1/r-RESPA⁵⁴ was used to integrate the equations of motion. Nonbonded short-range forces were computed for each time step, while long-range electrostatic forces were updated every 2 timesteps. The pressure was kept at 1.026 bar (1 atm) by the Nosé-Hoover Langevin piston,^{56,57} with a damping time constant of 50 fs and a period of 100 fs. The temperature was maintained at 300 K by coupling the system to a Langevin thermostat,⁵¹ with a damping coefficient of 5 ps^{-1} . A 150 mM background ionic concentration of NaCl was utilized to achieve system neutrality. The total system size was 94,691 atoms, comprised of 8,264 waters, 84 Na^+ ions and 88 Cl^- ions.

After 1,000 steps of Conjugate-Gradient minimization⁵⁰ with restraints on the protein and co-factor, and 10 ns of simulation with backbone restraints and restraints on the co-factor, a 50 ns production run in the NPT ensemble was carried out for each system.

Animal studies

For infiltration experiments, 8-12-week-old male and female C57BL/6J/Ly5.1/Ly5.2 mice were injected subcutaneously with 1×10^6 B16-OVA cells and conditioned 11 days later with peritoneal injection of 300 mg/kg cyclophosphamide (Sigma, #C0768). On day 14, 1×10^6 OT-I Ly5.2 CD8^+ T cells were peritoneally injected (the OT-I cells were previously activated and treated with 0.4 mM OE-S-2HG, OE-R-2HG or vehicle *in vitro* for 7 days). Animals were assigned randomly to each experimental group. On day 19, tumors, spleens, and lymph nodes (draining and non-draining) were harvested. The excised tumors were cut into small pieces and digested with 100 $\mu\text{g}/\text{mL}$ DNase I and 200 U/ml Collagenase at 37°C for 30 min. The spleens and lymph nodes were smashed over a 40 μm filter. Cells were counted, and where indicated, they were re-stimulated for 4 h with 100 nM OVA₂₅₇₋₂₆₄ peptide and brefeldin A and monensin were added for the last 2 h of activation. The tumor single-cell suspensions were stained with fluorochrome-labelled antibodies and analyzed by flow cytometry.

For tumor growth experiments, 8-15-week-old female C57BL/6J/Ly5.2 were inoculated subcutaneously with 0.5×10^6 B16-F10-OVA and conditioned 4 days later with peritoneal injection of 300 mg/kg cyclophosphamide. On day 7, 0.5×10^6 OT-I Ly5.1 CD8^+ T cells were peritoneally injected (the OT-I cells were previously activated and treated with 0.4 mM OE-S-2HG, OE-R-2HG or vehicle *in vitro* for 7 days). Animals were assigned randomly to each experimental group. Tumor volume was measured every 2–3 days with electronic calipers until day 60. Peripheral blood was collected from the tail vein at days 14 and 21 and analyzed by flow cytometry. Tumor volume was calculated using the formula $a \times b \times b/2$ where a is the length and b is the width of the tumor. Mice were sacrificed when the tumors reached a size of 500 mm^3 .

QUANTIFICATION AND STATISTICAL ANALYSIS

Results are shown as mean \pm SEM or mean \pm SD as stated in figure legends. Statistical analysis was performed with Prism-9 software (Graph-Pad). Statistical significance was set at $p < 0.05$ and the statistical tests used are stated in figure legends.

BioRender images

The graphical abstract and the panels Figures 4A and S3B were created with BioRender.com with agreement numbers GF25OEXDR7, LK25NAR4UU and UL25NAS2IF respectively.